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Abstract 
 
Head and neck squamous cell carcinoma (HNSCC) is a complex cancer that displays chemo 
resistance and a high mortality rate in patients with advanced disease. Early attempts at 
identifying new drugs to treat HNSCC relied on established cell lines transplanted into 
immunocompromised mice.  Despite numerous studies, very few, if any, of these studies 
have translated into improved outcomes for patients.  The main reason for this is thought to 
be the deficiencies of these xenotransplant models in reflecting the complexity observed in 
human tumours. 
More recently, patient derived xenotransplants (PDX) have emerged as a potentially 
informative model to interrogate cancer pathology, progression, clonal evolution and drug 
sensitivity. Whilst these models are being adopted widely by academia and industry there is 
still a paucity of data charcaterising their similarities and dissimilarities to patient tumours in 
situ.   In this thesis, I developed PDX models of HNSCC using NOD/SCID/IL2- receptor null 
(NSG) mice and used these models to see how closely they represented the original patient 
tumour in terms of histology, mutational profile, mutational complexity and clonal evolution. 
I then used these PDX models to investigate the efficacy of a drug lead from our laboratory 
with the aim of overcoming the known documented chemo-resistance of head and neck 
SCC’s to doxorubicin.  
In the first instance, I developed an aseptic technique for the establishment of human HNSCC 
samples in NSG mice. Once established, I was able to show that successful implantation of 
tumour samples was greater in tumours with higher malignancy and poorer histological 
differentiation than with well differentiated less aggressive tumours. Although there was 
variable time to palpable growth of tumours, I was able to show a strong correlation between 
time to initiation of a palpable tumour in the first and second passages of the PDX tumours. 
This correlation was so strong that it could be used to predict the time to establishment of 
HNSCCs in general following implantation.   
I used immunohistochemistry and immunofluorescence to investigate post tumour 
implantation events. These results showed that in the 2-4 week period following implantation 
there is a profound yet non-selective loss of viable tumour cells.  However, the residual 
viable tumour cells were sufficient to proliferate and recapitulate the histopathology of the 
tumour of origin.  My histopathologic and mutation profiling indicated that the phenotype 
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and genotype of the original parental SCC tumour remains stable in near term passages.  
Thus, the results of my study validate the use of PDX tumours as a robust model of human 
HNSCC in near term passage through mice and are therefore a relatively good representation 
of human HNSCC in which to conduct drug trials.  
Through the use of these PDX models I was then able to show that the novel drug 
combination of doxorubicin with a selective inhibitor of nuclear export (selinexor) induced 
substantial sensitivity to doxorubicin in the in vivo setting.  These data will be sufficient to 
justify a clinical trial of selinexor + doxorubicin in patients with relapsed HNSCC. 
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1.1  Background 
 
Cutaneous squamous cell carcinoma (CSCC) is the second most common human cancer [1]. 
Squamous cell carcinoma of the head and neck (HNSCC) accounts for over 90% of all head 
and neck cancers [2] and has an estimated global occurrence of 600,000 new cases per year . 
Thus, CSCC and HNSCC are common malignancies afflicting humans. A number of 
carcinogens have been implicated in the development of SCC including UV radiation, cigarette 
smoke, tar, alcohol and oncogenic Human Papilloma Virus infection [3]. Furthermore, the 
effects of immunosuppression also increases risk of SCC such that death from CSCC is the 
leading cause of death in kidney transplant patients.  HNSCC in particular is often advanced at 
the time of diagnosis with relatively low long-term survival rates [4]. Current treatments consist 
of extensive surgery, radiotherapy and/or chemotherapy. These treatments are often 
accompanied by a relatively low survival rate due to disease relapse and the emergence of drug 
resistance [5]. Despite recent advances in the early detection, diagnosis and treatment of 
HNSCC, the 5 year survival rate for patients has remained at 60% for the past 25 years (Figure 
1) [6]. Part of the failure to develop new curative treatments may be the availability of clinica l ly 
relevant models of SCC for drug 
discovery. 
As a consequence, research has 
focused on establishing preclinica l 
models that mimic the histologica l, 
genetic and molecular changes that 
accompany neoplastic 
transformation and the emergence 
of drug resistance. Two different approaches have been used thus far in preclinical tests. These 
include cell based in vitro systems and in vivo animal models. Unfortunately, there has been a 
poor correlation between the preclinical findings in these models and the efficacy of these 
compounds in clinical trials [5].  Thus, despite encouraging preclinical results, most drugs are 
found to be ineffective late in their development with only ~5% of patients in phase 1 clinica l 
trials responding to that treatment [7].  
Head and neck SCC is a heterogeneous disease associated with cumulative genetic and 
phenotypic alterations that drive malignant conversion and then metastatic progression [8]. 
These alterations have been shown to drive the inactivation of multiple tumour suppressor 
Figure 1: Five year survival from head and neck cancers 
3 
 
genes through deletions, point mutations, promoter methylation, gene amplification or 
activating mutations or translocations, amplification or de-repression of oncogenes [8].  
Following the acquisition of mutations sufficient for malignant conversion, tumours start to 
evolve through a process of clonal expansion, genetic diversification and clonal selection 
within their tissue environment [9].  This process is referred to as clonal evolution. During 
clonal evolution, successive divisions of cancer cells lead to a high degree of genetic and 
epigenetic heterogeneity within the tumours. This heterogeneity is of clinical relevance since 
it drives the expansion of drug resistant clones in the tumours of patients receiving therapy 
[10,12]. It also leads to the selection of variants with phenotypes that drive metastasis and drug 
resistance [11].  For these reasons, it is not surprising that some of the traditional models used 
to predict the sensitivity of tumours to novel therapeutic agents have failed to translate into 
new cures for SCC patients.  These advances indicate that if we are to find new treatments for 
SCC we will need to develop new preclinical models that better reflect human tumours in situ. 
In this regard we need to consider the strengths and weaknesses of current models and then 
identify possible new models that may be more relevant to the human condition.  
 
1.2 Current pre-clinical models 
 
The use of rodent tumour models in the study of tumour behaviour and preclinical testing of 
new drug therapies is well established because of the mouse’s relatively similar physiology to 
humans [12]. These include constitutive transgenic or knockout mouse models or, those models 
generated through the implantation of well-established tumour cell lines into immunodefic ient 
mice (xenotransplants). These models have been useful in identifying potential mechanisms 
underlying metastasis and in the selection of tumour subtypes for further exploration [13]. 
However, they have their limitations in that they often do not sufficiently represent the genetic 
and phenotypic complexity of the cancer from which they were originally derived [13].  As a 
result many oncological drugs have advanced to phase II/III clinical trials only to end up failing 
because the drug activity seen in the cancer models does not translate to meaningful human 
patient responses [14]. This lack of efficacy is largely because the conventional preclinica l 
models used fail to replicate the genetic and phenotypic complexity seen in human cancers. 
Below is a discussion of the mouse models historically used to represent human cancers and 
the limitations that have led to the development of the patient-derived xenotransplant models 
(PDX). In contrast to the aforementioned mouse models, PDX models have been shown to 
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more faithfully reproduce the cell-autonomous drivers of tumour heterogeneity [11]. In my 
project I will look at the PDX models of HNSCC to see how closely they mimic the phenotypic 
and genetic complexity seen in human HNSCCs in situ. In addition, I will use the PDX model 
to compare drug efficacy with a traditional cell line xenotransplant model of SCC.   
 
1.3 Cell line models 
 
The earliest models used in cancer research involved cells isolated from patient tumours and 
maintained in culture.  These in vitro cell line models have been used extensively in cancer 
biology for studying drug responses and tumour biology. However, conventional preclinica l 
models using in vitro cell lines, have been shown to have poor clinical relevance to most 
cancers with the exception of non-small cell lung cancer [15].  This is, in part, due to their 
inability to form appropriate tumour structures when transplanted into immune deficient 
recipient mice.  This is reflected in the absence of a tumour microenvironment due, in part, to 
discordance between cytokines and cytokine receptors between human and murine species 
[16]. In addition, the selection pressure placed on these cells in serial passages in vitro tends to 
select for a subset of cancer cells that have adapted to grow outside the natural tumour 
microenvironment [15]. This results in the emergence of phenotypically and genetica lly 
different cells to those in the parental tumour or to the expansion of very selective subclones 
from the cell cultures [17]. In addition, established or patient-derived cell lines do not reflect 
the complex intratumoral heterogeneity and molecular diversity of human cancers when 
implanted into mice [18].  Supporting this, Hausser et al (2005) suggested that cell lines may 
show a more homogenous, undifferentiated histology simply due to selection and adaptation to 
the relatively homogeneous environment within tissue culture [19]. This is certainly the case 
for HNSCC cell lines used routinely in our laboratory [20,21,22]. 
Human cancer cell lines that are injected subcutaneously into immunodeficient mice are 
usually derived from advanced, aggressive and poorly differentiated tumours that lack their 
original tumour-associated stroma [23]. This selection for a specific histopathological 
phenotype biases tumour studies to reflect a very selective histopathological features. The 
stroma within tumours has been shown to be critical in sustaining tumours tissue architecture 
which is important in the pathogenesis of cancer progression, growth and metastasis [23]. 
This is especially true of well-differentiated or low-grade tumours that depend on complex 
stromal-epithelial relationships for growth [23]. The ability of a rodent tumours model to 
5 
 
replicate metastatic potential is especially significant as they are the main determinants of 
prognosis and are thus the target of systemic therapy [24]. Consequently, these models have 
limited value in reliably predicting the efficacy and possible toxicities of a given anticancer 
drug when applied to human cancer patients and this, in turn, limits their value as a means of 
identifying new drug targets and consequently they are poor at informing patient management 
strategies. 
 
1.4 Transgenic Mouse models 
 
Based on findings from cell line studies and later data emerging from sequencing human 
tumours there was a move to generate genetically engineered mice that express or are deleted 
for genes and mutations thought to be involved in cancer formation and responses.  Transgenic 
and ‘knockout’ mice have been used as in vivo models to study SCC epidermal tumorigenes is 
in colorectal, pancreatic and non small cell lung cancers, to name a few. These oncogene-driven 
genetically engineered mouse models have been shown to reproduce some therapeutic 
responses, or lack thereof, to an array of commonly used cytotoxic agents and therapeutic 
targets like epidermal growth factor (EGFR and vEGFR) [25]. Genetically engineered mouse 
models have previously been used to study tumour biology including the mechanisms of 
tumour initiation, progression and maintenance and indeed are well suited to studying drug 
responses within a well-defined genetic background in specific cancer genotypes [26]. Indeed 
they have proved useful in determining whether particular genetic lesions are causal 
contributors to tumour development and behaviour.  However, a significant limitation of these 
models is they are relatively homogeneous and lack the genetic diversity observed in human 
tumours [26].  This is likely due to them arising within a context of a specific serious mutation 
and not acquiring the thousands of other mutations that generally accompany oncogenesis.  For 
this reason their genetic diversity and their relative lack of clonal evolution limits their value 
as a preclinical screen for new drug targets in cancers.  Having said that, the obvious advantage 
of these models is that the tumours are syngeneic and consequently the stroma and immune 
responses are intact [27, 28]. In contrast, a disadvantage of transgenic mouse models is that 
they often take a relatively long time to develop tumours which when coupled with their lower 
mutational spectrum and lack of intratumoral heterogeneity compared with human tumours 
limits their value [29]. Thus, they are an essential model to prove causality in an in vivo setting 
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but lack the complexity required to be used as a preclinical screening platform of human tumour 
behaviour.  
 
1.5 Carcinogen-induced models 
 
These models have been used to study the progression of tumour pathogenesis in response to 
environmental carcinogens and tumour promoters [25]. Some of these models include exposing 
experimental models to chemical carcinogens such as coal tar, cigarette smoke, DMBA (7,12-
dimethylbenzanthracene) and BaP (benzo[a]pyrene) to induce SCC models of skin and upper 
aerodigestive tract oral mucosa. However, whilst carcinogens like DMBA do induce cutaneous 
SCC these tumours are poor mimics of the original human lesion as they often do not possess 
the histological features of a differentiated SCC and possess a different mutational spectrum to 
those of spontaneously arising human SCCs [30]. A more closely representative model is seen 
with the carcinogen 4-nitroquinolone 1- oxide (4-NQO) which has been shown to induce oral 
cavity SCCs in rats and mice [31]. 4-NQO is a water-soluble quinolone derivative that forms 
DNA adducts through the substitution of adenosine for guanosine and can also cause mutations 
and DNA strand breaks through the production of reactive intracellular oxygen species [32]. 
The 4-NQO induced mouse model has been shown to express many genes that are similar to 
the tumorigenesis produced by tobacco exposure that is seen in patients with  head and neck 
SCCs [33]. Other examples of carcinogen- induced moue models are seen with ultravio let 
induced murine tumours where mutations in the TP53 tumour suppressor gene have been 
shown to be involved in the development of UV-induced carcinomas [36].  
These carcinogen- induced pre-clinical cancer models have proved a useful tool in cancer 
biology as they generally produce a high incidence of organ-specific lesions and have been 
shown to have similar molecular, biochemical and histopathological features to the 
development of  specific human cancers [25]. In particular, these tumours arise within the 
context of an appropriate stromal and immune environment which is a significant advantage. 
The use of these models however has been restricted predominantly to cancer chemo-
preventative studies, and not the evaluation of therapeutic agents primarily because of the 
prolonged timeframes and associated animal maintenance cost required in order to develop 
these carcinogen- induced models [25].  
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1.6 Patient derived xenograft models 
 
The limitations of other preclinical models in drug screens and target identification prompted 
the search for more relevant and tractable models of human tumours that can be used to identify 
new targets and aid in the expeditious translation of target identification to clinical management 
of patients with cancer.  In this regard, the development of xenograft models using patient-
derived human tumour tissue (so called PDX models) has become increasingly important in 
addressing the inconsistency between the original patient tumour and experimental models. 
These models have been shown to more faithfully predict the subsequent clinical success of 
novel anticancer therapies in patients [35] and present the best representation we have of 
disease pathology and physiological response [27]. PDX models are established from the 
explant transfer of patient samples which are implanted in immunosuppressed mice (Figure 2). 
                            
(http://www.thescientist.com/April2015/feature2_infograph.jpg) 
Figure 2: Schematic diagram of mouse PDX model showing passage of tumour tissue 
from human to 1st and subsequent second generation mice 
PDX rodent models are thought to more accurately reflect human tumours biologica l 
characteristics, molecular diversity and cellular heterogeneity in comparison to tumour cell 
lines alone. These histologically intact fresh tumour tissues have been shown to grow in a 
variety of graft sites in athymic nude mice, severe combined immune deficient (SCID) mice, 
nonobese diabetic (NOD)-SCID mice and recombination-activating gene 2 (Rag-2) knockout 
mice [37].  After a period of indolent growth, these xenografts enter a growth phase that is 
suitable for harvesting and re-implantation into successive generations of mice. They usually 
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achieve a relatively high engraftment rate which makes them a useful tool for studying a wide 
range of cancers [35]. 
 
1.6.1 Advantages of PDX models 
The ideal animal model should closely resemble the pathology and physiology of the origina l 
primary human tumour [13]. Previous studies have shown that PDX xenograft models retain 
similarities to their original donor tumours both in histopathological, genetic and biologic a l 
characteristics and appear to maintain relatively stable differentiation and morphology between 
serial passages through mice [38]. Analysis of gene expression profiles show many similarit ies 
between donor tumours and their corresponding PDX, with only genes involved in the stromal 
compartment and immune function being less represented in murine models, because of the 
replacement of human stroma with murine elements [37]. In one study of serial passages of 
breast cancer PDX though mice there was evidence of the loss of genetic complexity and the 
acquisition of a more homogeneous genotype with increasing passage of the original tumour 
[39]. However, overall, PDX xenograft models have been shown to more closely resemble the 
architecture and behaviour of the originally implanted primary tumour than other models. Thus, 
PDX’s represent a potentially tractable model for the preclinical testing of patient responses to 
various chemotherapeutic regimens. In addition, they represent a good model to analyse tumour 
progression at both a cellular and molecular level and the identification and evaluation of the 
effectiveness of novel anticancer therapeutic agents. Consequently, PDX models are being used 
for biologic studies, preclinical drug evaluation and biomarker identification as a means of 
classifying tumour responsiveness to treatment. 
Indeed, PDX models have shown good predictive power in the treatment of colorectal, non-
small cell lung cancer, breast cancer and renal cell cancer [40]. The response rate of drugs used 
in the standard of care for different types of tumours has been tested in PDX models with good 
correlation between their chemoresponsiveness and clinical outcome in the donor patient [38].  
For example, Fibig et al (2004) showed that xenograft models were able to correctly predict 
response to ‘standard’ chemotherapeutic agents in 90% of tumours and to resistance in 97% of 
patients. PDX models may also have application to the identification of potential drug efficacy 
and resistance biomarkers [41]. Multilayered biological assays can be performed on early-
passage PDX models to characterize them for biomarker development as a means of evaluat ing 
tumour responsiveness to treatment [42]. For example, in colorectal cancer PDX models with 
the KRAS-mutant gene have been shown not to respond to cetuximab and thus represent a 
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well-documented clinical biomarker for targeted therapy [43].  Another important use for PDX 
models is in simulating resistance when exposed to treatment strategies used in clinical settings. 
This has been seen in ovarian cancer where prolonged exposure to cisplatin resulted in 
resistance in a platinum-sensitive model that is similar to that observed in patients [38]. 
Therefore PDX models may be informative in drug-response studies to help select patient 
populations that are most likely to be sensitive to a novel anticancer agent [38].  They also 
allow the mechanistic study of the action of these agents that are not possible to be studied, for 
ethical reasons, in patient populations. 
PDX models may also be useful in evaluating the effectiveness of current therapeutic regimens 
to determine optimal treatment schedules and potential combinations of known drugs [13]. This 
is particularly important in an era where we are moving towards a more personalized approach 
to treatment and where parallel studies in rodent models (often referred to as “avatars") and 
patients can be used to select the most appropriate treatment for an individual patient. This is 
significant as tumour histopathology tends to differ significantly from one patient to the next. 
PDX xenograft models are therefore thought to possess three applications in the study of cancer 
behaviour and treatment [13]: 
1. Use as an in vivo screening tool to test new drugs with therapeutic potential 
2. Use in the evaluation of markers of response and resistance to drugs used in cancer treatment 
3. Application of personalized chemotherapeutic regimens by assessing the chemosensitivity of 
tumors to current anticancer agents in vivo. 
 
1.6.2 Limitations of PDX models 
PDX are not without their own set of limitations. For example, it has been shown that the 
stroma within human tumour tissue implanted in mice is eventually replaced by murine stroma 
throughout tumour growth in mice [35]. As a result, when the models are used for drug testing, 
the stroma is essentially murine which is a potential limitation in studying human tumour 
growth since tumour:stroma interactions are known to be important in tumour biology as potent 
drivers of invasion and metastasis [44]. This is especially relevant to those studies involving 
species-specific anticancer compounds that target the tumour microenvironment. Another 
important caveat on the use of these models is that they can only be generated in 
immunosuppressed mice. Whilst, immune system reconstitution can be performed it is 
challenging and cannot be truly humanized at this time.  Other features that may be changed in 
xenograft models include tumour tissue architecture and disruption of lymphatic and vascular 
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supply [16]. Human cancers are often heterotopically transplanted into mice at a different 
location from where they originally arose and this also can reduce the engraftment rate of cells 
with tumorigenic potential. Indeed, previous studies have shown that PDX xenograft to 
subcutaneous sites are associated with a relatively low tumour-bearing rate (~40-60%) and only 
succeed in growing in cases of highly advanced malignancy [13]. In contrast, orthotopic 
models, although more technically challenging have the advantage of a similar 
microenvironment from which the original tumour arose. This may be important because 
chemosensitivity and vascularisation have been shown to be affected by tumour 
microenvironment [45]. 
In addition, it is not yet established whether the mechanisms of resistance that develop from 
these models will have the complexity and heterogeneity seen in the spectrum of acquired 
resistance mechanisms that drive the development of human tumours [28]. Kemper et al 
showed that the BRAF amplification that was responsible for conferring resistance, was 
heterogeneous even within a single metastasis, suggesting that multiple resistance mechanisms 
can be present within a single tumour [46]. Thus, whether PDX samples can be used to model 
a tumours genetic heterogeneity remains to be confirmed.   
It is established that differences between mouse and human tissue environments may impair 
survival, proliferation and engraftment of human cells in mice because of incompatibilit ies 
between mouse ligands and human receptors for certain growth factors and adhesion molecules  
[47].  The engraftment frequency and growth rate of implanted tumours is highly variable and 
often depends on tumour type (Table 1). It has been shown that more aggressive tumours have 
a higher rate of “ take” when generating PDX models [38]. According to Williams et al (2013), 
some tumours might struggle to engraft because of dependence on microvascular cues not 
present in mouse stroma, absence of appropriate support matrix and/or growth factors and a 
dependence on haematopoietic cells [18]. There is also the issue of time to model generation 
which is variable and can span up to 6 months which is often an unacceptable length of time 
for patients to wait before commencing treatment. Tumour ‘take’ can also depend on implant 
location and recipient strain, with engraftment rates typically varying between 23-75% 
depending on tumour type [48].  
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Table 1: Engraftment success rates in different PDX Models [38]. 
Tumour 
type 
Available 
models O rigin Procurement Processing Mice strain 
Implantation 
site 
Engraftment 
rate  
CRC 130 Metastasis Surgery 
Fresh tumour 
pieces in 
Matrigel NOD/SCID s.c. 87% 
CRC 54 
Primary 
(35) Surgery 
Fresh tumour 
pieces Nude s.c. 64% 
  
Metastasis 
(19)      
CRC 41 Primary Surgery 
Fresh tumour 
pieces Nude Orthotopic 89.1% 
HBC 25 Primary Surgery 
Fresh tumour 
pieces Nude s.c. 13% 
HBC 12 
Primary 
(4) 
Surgery/fluid 
drainage 
Fresh tumour 
pieces in 
Matrigel 
NOD/SCID 
with 
estrogen 
supplementat
ion for ER
+
 
tumours 
Mammary fat 
pad 27% 
  
Metastasis 
(8)      
HBC 24 Primary 
Biopsies/surgery/
fluid drainage 
Fresh tumour 
pieces 
SCID/Beige 
and NSG 
w/wo 
estrogen and 
immortalized 
human fibro-
blasts 
Mammary fat 
pad 3%–21% 
NSCLC 25 Primary Surgery 
Fresh tumour 
pieces NOD/SCID s.c. 25% 
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Tumour 
type 
Available 
models O rigin Procurement Processing Mice strain 
Implantation 
site 
Engraftment 
rate  
NSCLC 32 Primary Surgery 
Fresh tumour 
pieces NOD/SCID Renal capsule 90% 
PDAC 42 Primary Surgery 
Fresh tumour 
pieces in 
Matrigel Nude s.c. 61% 
PDAC 14 Primary Surgery 
Fresh tumour 
pieces in 
Matrigel Nude s.c. NR 
PDAC 16 
Primary 
(11) Surgery 
Fresh tumour 
pieces Nude Orthotopic 62% 
  
Metastasis 
(5)      
SCCHN 22 Primary Biopsy/surgery 
Fresh tumour 
pieces in 
Matrigel NSG s.c. 85% 
SCCHN/S
CC 21 Primary Surgery 
Fresh tumour 
pieces in 
Matrigel Nude s.c. 54% 
Uveal 
Melanoma 25 
Primary 
(73) Surgery 
Fresh tumour 
pieces NOD/SCID s.c. 28% 
  
Metastasis 
(17)  
    
Abbreviations: CRC, colorectal cancer; FOM, floor of mouth; FOT, floor of the tongue; HBC, human breast cancer; NR, not reported; PDAC, 
pancreatic ductal adenocarcinoma; RCC, renal cell cancer; s.c., subcutaneous implantation; SCC, squamous call carcinoma; SCCHN, 
squamous cell carcinoma of the head and neck 
The reasons for the low transplant rate in some PDX models is poorly understood. However it 
has been recently shown that tumour cell engraftment into a foreign host may exert a selection 
pressure which “changes the clonal composition of the engrafting tumour [49].”  Eirew et al 
(2015) have used single cell sequencing to show that only a limited number of clones expand 
in breast cancer PDX models [50]. In particular, there appears to be a selective outgrowth of 
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more malignant and, in particular, metastatic cells [51]. Therefore, the resulting xenograft 
tumour may arise from a small percentage of the originating parental tumour cells, although 
interestingly, these clonal populations appear to be stable in terms of gene expression and 
histology in subsequent passages through mice [52]. This would suggest that most of the 
changes in clonal prevalence appear to “reflect selection acting on pre-existing clones, rather 
than the generation of new clones [49].” 
In addition, many patient-derived xenografts are established from the primary tumours of 
“chemo-naïve” patients and thus they do not accurately reflect the chemotherapy-refrac tory 
patient population in whom most novel therapeutics will undergo their initial trials [52]. 
Another limitation of using immune-deficient mice is that their immune system is variably 
compromised which will impact on tumour growth, progression and treatment responses [53]. 
Syngeneic models using murine cell lines that were injected subcutaneously into immune -
competent murine hosts were used to avoid the immune deficiencies found in the xenograft 
models [54]. However, they too showed a poor correlation between the therapeutic activity 
seen in these syngeneic models with their efficacy in humans, thought to be due to key 
differences seen between mouse and human immune systems in areas like signalling pathways 
and immune cell receptor expression [54].  
Murine models also show imperfect modelling of drug distribution and metabolism and these 
pharmacological differences between species might also provide a possible explanation as to 
why some “anticancer agents appear effective in ‘in vivo’ mouse models but fail to show 
efficacy in phase II trials [55]”. Finally, there is an increasing use of immune-based therapies 
in clinical practice which limits the use of these immunosuppressed mice. However, there has 
been a recent move to ‘humanise’ the immune system by transplanting purified human CD 34+ 
hematopoietic stems cells in myeloablated NOD/SCID/IL2R deficient mice (NSG) [24]. 
Morton et al (2015) have shown that humanized mouse models can potentially recreate the 
patient tumour-immune microenvironment and thus can be used to: i) model the response to a 
fully intact human immune system and/or ii) investigate the use of new immunomodula tory 
chemotherapeutics [44]. However, this remains technically challenging as not all immune lines 
are recoverable from stem cell transplants [49], in addition to the limitations of human bone 
marrow acquisition and variable engraftment rates. 
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1.7 Conclusion 
 
PDX models represent a potentially exciting model for the development of novel therapies and 
for assisting in clinical trial design and integration into personalized medicine strategies that 
enable selection of the best therapy for an individual patient. These models may also be 
valuable in predicting the starting dose for phase I studies as well as quantitatively and 
qualitatively predicting human toxicity [15]. While it is hoped that they will play a more 
significant role in drug development there are still a few critical issues and challenges that need 
to be addressed in order for them to be a useful and informative platform for cancer 
management and treatment. Consequently, it is vital that such models be optimized for their 
engraftment and growth in order to be able to accurately draw conclusions with regards to their 
amenability to pharmaceutical intervention and their corresponding ability to reduce early drug 
development failures [40].  In particular, there is a clear need to characterise individual tumour-
specific PDX models.  In this regard, there is very little information available in relation to 
SCC PDX models.   
 
1.8 Hypothesis 
 
That patient xenotransplant models of head and neck SCC’s raised in NSG mice are similar in 
both histology and genomics to the primary patient tumour and thus represent a robust model 
which can be used to investigate HNSCC, and conduct clinical trials that have the potential of 
treating  patients with HNSCC. 
 
1.9 Aims 
 
1. To develop an in vivo PDX model of head and neck SCC by using small pieces of 
patient tumours obtained at the time of surgery and implanting them into 
NOD/SCID/IL2R (NSG) mice.  
2. To use a combination of histopathology and genomics to compare the primary lesion 
to that of the lesion passaged through a mouse to see how closely the patient 
xenotransplant models of SCC represent the primary patient lesion.  
3. To use the xenotransplant model if SCC to test the validity of drug leads from our 
laboratory.  
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CHAPTER 2: Establishment of a Xenotransplant 
model of head and neck SCC 
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2.1 Introduction 
 
PDX models are a pre-clinical tool that has utility for in vivo screening of novel chemo-
therapeutic agents and understanding tumour biology. However, it is important to be aware of 
the advantages and the failings of the PDX system.  For example, it is known that clonal 
selection and genetic drift can occur in the context of serially passaged breast cancer PDXs 
[50].  Countering this, there is good evidence, at the transcriptomic and proteomic level, that 
head and neck cancer PDXs share similarities with their tumour of origin [56]. The main aim 
of my project is to clearly define whether PDX models truly reflect the histopathology and 
mutational signatures seen in human HNSCC in situ. The first step is to establish a 
reproducible technique for the generation of head and neck cancer PDXs. The second step is 
to characterise the timeline for tumour initiation and growth as this will give key insights into 
whether selection pressures are placed on the implanted tissue. These initial studies are 
essential prior to studies on the similarities in mutational and histopathological features of the 
PDX tumours and those of the donor tumour. The generation of PDX models will expand the 
available animal models for HNSCC and has the potential to best reflect the complexity 
within and between human HNSCCs. In this chapter I will report on the technique used to 
establish a HNSCC PDX.  
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2.2 Materials and Methods 
 
2.2.1 Human Biopsy Collection  
All sample collection was done with current Institutional Human Ethics Approval. Suitable 
HNSCC patients were identified prior to surgery and were consented. At the time of surgery, 
fresh surgical SCC tissue samples (3 mm punch biopsies) were obtained from patients with 
primary and secondary squamous cell carcinoma.  Specifically, tissue that was not required 
for pathological diagnosis was identified within the resected specimen and small 3 mm punch 
biopsy samples were taken for my study.  Tumour biopsies were then dissected into three 
equal portions and 1/3 of the tumour was stored in RNALater (Ambion thermofisher 
scientific, Waltham, MA USA) and frozen at -80ºC for DNA/RNA downstream analysis.  
Another 3 mm3 piece was fixed in 10% v/v neutral buffered (4% formaldehyde) formalin 
(Austral Biostain P/L, Traralgon Victoria) for histology. The final 3 mm3 piece was used for 
the PDX implantation. 
2.2.2 Human biopsy decontamination  
Tumour tissue was submerged for 1 minute in a solution of 2 mg/ml chlorhexidine gluconate, 
ethanol 96 ml/l and saccharin (Savacol, Colgate, Sydney Australia) prior to two washes in 
phosphate-buffered saline (PBS). Tissue was incubated overnight at 37 o C in Keratinocyte 
Serum-Free Medium (Gibco, Gaithersberg, MD, USA) supplemented with penicillin (10 
ng/ml, Gibco), streptomycin (10 ng/ml, Gibco), gentamicin (10 ng/ml, Pfizer, New York NY 
USA) and amphotericin B (200 ng/ml, Invitrogen thermofisher, Waltham MA, USA). 
2.2.3 Lysis of microbes prior to colony PCR  
The media that the tissue was incubated in was collected and the tubes were centrifuged at 
4°C at 2817 g for 5 minutes to collect the bacterial debris. The supernatant was discarded and 
the pellet was resuspended in 15 µL of colony PCR lysis buffer containing 10 mM Tris-Cl, 
pH 7.5, 1mM EDTA+ 0.1% Triton X100). Samples were boiled at 94o C for 5 minutes and 
centrifuged at 16 116 g for 10 minutes. These samples were used to assay for the presence of 
bacterial DNA as a means to measure the effectiveness of our sterilization technique. 
2.2.4 Polymerase Chain Reaction (PCR) for bacteria  
PCR was performed with a final volume of 50 µl containing 5 µl of 10X ThermoPol Buffer 
(New England Biolabs, Massachusetts USA), 200 nM forward primer EUB 5` 
TCCTACGGGAGGCAGCAGT, 200 nM reverse primer EUB 3’ 
GGACTACCAGGGTATCTAATCCTGTT (IDT DNA, Bulkham Hills NSW)[3], 200 µM  of 
dNTP’s (dATP, dCTP, dGTP, dTTP) Bioline, London UK), 0.25 U Taq Polymerase (New 
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England Biolabs), 39.75 µl of sterile water and 2 µl of bacterial DNA.  Aliquots of 2 µl of the 
Yersinia enterocolitica DNA (kindly donated by Mary Ellen Costello, Brown Laboratory, 
UQDI) was used as a positive control. The PCR amplification parameters were as follows:  
an initial denaturation at 94°C for 2 minutes followed by 28 cycles of denaturation at 99°C 
for 15 seconds, annealing at 51.2°C for 30 seconds and extension at 72°C for 45seconds. The 
final extension was conducted at 72°C for 5 minutes. After PCR, 10% of the PCR reaction 
was electrophoresed on a 1.2% agarose gel stained with ethidium bromide (Sigma Aldrich, St 
Louis MO, USA) and visualized under UV transillumination. 
2.2.5 Animal Studies  
NOD/SCID/IL2- receptor null (NSG) mice were obtained from ARC (Murdock, WA). 
Animals were housed in cages in the biological resources facility at the Translational 
Research Unit in Brisbane. Animals were fed with a fixed formula ration containing Wheat, 
barley, Lupins, Soya meal, Fish meal, mixed vegetable oils, Canola oil, Salt, Calcium 
carbonate, Dicalcium phosphate, Magnesium oxide, and a Vitamin and trace mineral premix. 
All animal studies were in accordance with the policies of the animal welfare unit at the 
University of Queensland and conducted with Institutional Animal Ethics Committee 
approval.   
Biopsy implantation into NSG mice: Following an overnight incubation in the antibiot ic 
“cocktail”, the tumour biopsy specimen was coated with 250 µl of Falcon Matrigel (Invitro 
technologies, Noble Park North, Victoria) and transported on ice to the animal facility prior to 
implantation.  Biopsies remained on ice for no more than 30 minutes prior to implantat ion. 
Mice were anaesthetized using gaseous induction with 100% isofluorane (Abbott, Chicago IL, 
USA). The neck of the mice was shaved and the surgical site swabbed with betadine. A surgica l 
implantation site was generated on the left neck nape by creating a subcutaneous incision using 
scissors (Pfizer). The tumour sample was inserted into this pocket and the surgical site closed 
using Vetbond glue (3M, St Paul MN, USA) (Figure 3). Mice were monitored weekly for signs 
of infection and tumour growth. The longest diameter of the tumour was measured weekly 
using calipers.  
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2.2.6 Immunohistochemistry (paraffin embedded tissue sections) 
Tissue samples taken out of the NSG mice once they had reached a tumour burden of ~1cm 
were fixed overnight in 10% neutral buffered formalin prior to dehydration and embedding in 
paraffin. (Crystal Chang, Translational Research Institute Histology Facility). Five micron 
tissue sections were placed on superfrost plus slides (thermos scientific, Scoresby VIC, 
Australia) and stained with haematoxylin and eosin (TRI Histology Facility) for 
histopathological assessment. The slides were also prepared for immunohistochemistry by 
incubating them at 60 oC for one hour to deparaffinise the samples. The sections were then 
de-waxed with 100% xylene (Point of care Diagnostics, Artarmon, Australia) for 5 minutes 
followed by rehydration in an ethanol series starting with absolute 100% ethanol and 
progressing through 95% v/v, and 75% v/v of ethanol for 5 minutes each and then finally into 
buffer. Antigen retrieval was performed using 10 mM sodium citrate solution (pH 6.0) 
(Sigma – Aldrich) with 0.05% v/v Tween 20 (Chem supply, Gillman South Australia). Non-
specific antibody binding was blocked with 10% Bovine Serum Albumin (BSA) (Fisher 
Biotec, Bunbury Western Australia)/1X PBS (137 mM NaCl, 2.7 mM KCl, 10 mM 
Na2HPO4, 1.8 mM KH2PO4 at pH 7.4) one hour followed by an overnight incubation in a 
humid chamber at 4 oC with the following antibodies:  
1. Rabbit anti-cleaved caspase III (Cell Signalling #9661)-1:300 dilution used as a marker for 
apoptosis  
Figure 3: A tumour sample was implanted in the nape of the 
neck of the NSG mice and closed with glue using isoflurance 
anaesthesia administered through a nose cone. Mice were 
anaesthetised for approximately 15 minutes in total and took 
3-5 minutes to recover.  
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2. Mouse anti-human cytokeratin 5/6 antibody (Novus Biologicals NB 100-2756)-1:100 
dilution used as a pan epithelial marker to detect human cells. Rabbit or mouse IgG was 
diluted at the same concentration as the primary antibody as a negative control. Following 
overnight incubation with the primary antibody sections slides were washed with PBS 
containing 0.025% Triton X (3x for 5 minutes each) and incubated with 0.5% solution of 
hydrogen peroxidase (Sigma Aldrich) for five minutes.  
3. Bromodeoxyuridine (BrdU) used as a marker for cell proliferation- Mice underwent intra-
peritoneal injections with 20ul/g of 10µM of 2-Bromo-2-deoxy-uridine (MW 07.1g, Roche, 
Manheim Germany) 3 hours prior to sacrifice to enable proliferation to be estimated in the 
paraffin sections. 1:100 dilution of BrdU was incubated for 1 hour at room temperature after 
incubation of the slides with 3% solution of hydrogen peroxide (Sigma Aldrich) for five 
minutes.  To detect BrdU positivity, slides were incubated for one hour with anti-Rabbit or 
anti-Mouse IgG Secondary Antibody conjugated with Horseradish peroxide and Cardassian 
DAB chromogen (Biocare Medical, Pacheco CA, USA). Slides were then dehydrated by 
incubation through an ethanol series (75%. 95% then 100%), incubated with 100% xylene 
and mounted using DPX neutral mounting medium (Thermo Scientific). Slides were allowed 
to dry at room temperature overnight and on the next day slides were visualized and imaged 
on an Olympus V120 slide scanner.  
Quantitative analysis of immunohistochemistry: BrdU assessment was made using a cell 
counter in the Image J Fiji (NIH, USA) program. The number of nuclei that stained positive 
for BrdU/ cytokeratin5/6 (ie tumour-specific BrdU) was expressed as a percentage of the total 
amount of nuclei present within the SCC at 5 random areas on the slide. The percentage of 
tumour tissue (cytokeratin 5/6 positive) that was positive for cleaved caspase III was 
estimated in relation to surface area of SCC tissue within the slide.  
2.2.7 Co-localisation using Indirect Immunofluoresence (Paraffin embedded 
tissue sections) 
Paraffin embedded sections were de-waxed and rehydrated as per immunohistochemistry 
(Section 2.2.6) protocol with the addition of a final 50% ethanol wash for five minutes. Heat-
mediated sodium citrate antigen retrieval was carried out as that described for  
immunohistochemistry (Section 2.2.6). After antigen retrieval, the sections were washed in 
PBS with 0.3% v/v Triton X 100 twice, followed by blocked in 10% goat serum (Sigma 
Aldrich) in PBS with 0.3% v/v Triton X 100 for one hour at room temperature. The 
antibodies used were the same as those used for immunohistochemistry (Table 2). The 
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primary antibody was diluted in blocked buffer and incubated on the slides for one hour at 
room temperature. The primary antibody was removed and the slides were washed in three 
changes of PBS with 0.1% v/v Triton X 100 for 15 minutes. The secondary antibody was 
diluted in blocking buffer blocking buffer and incubated on the slides for one hour at room 
temperature in a light proof container. The secondary antibody was removed and the slides 
were washed once in PBS with 0.1% v/v Triton X 100 and twice in PBS in a light proof 
container. The process was repeated for the third and fourth antibody. The slides were rinsed 
briefly in distilled water and incubated with 1:1000 DAPI in PBS for 10 minutes. The DAPI 
was removed and the slides washed in three changes of PBS. A 22 mm coverslip (Menzel-
Glaser, thermoscientific) was mounted on the tissue sections with Prolong Gold (Cell 
signalling, Danvers USA).   
 
Table 2: Antibodies used for indirect immunofluorescence on fixed cells. IgG was used 
as the isotype control at the same concentration as the corresponding primary antibody. 
Antigen Species Antibody Dilution 
Cytokeratin 5/6 [mAb] Mouse Novus Biologicals NBP1-22534 1:100 
Cleaved caspase III [pAb] Rabbit Cell Signalling #9661 1:300 
Mouse anti-human IgG [mAb] Mouse Santa Cruz #F112 1:100 
Rabbit anti-human IgG [pAb] Rabbit Dako #F018501 1:300 
Bromodeoxyuridine (BrdU) [mAb] Rat Abcam [BU1/75 (ICR1)] 1:200 
Anti- mouse AlexaFluor 488 [pAb] Goat Molecular Probes #A11001 1:200 
Anti-rabbit AlexaFluor 594 [pAb] Goat Molecular Probes #A11014 1:600 
Anti-rat AlexaFluor 594 [pAb] Goat Molecular Probes #A11 1:400 
 
2.2.8 Microscopy 
Immunofluorescent images were visualized and imaged on Confocal Microscope FV 3000 
(Olympus).  
 
2.2.9 Histopathological Examination 
Five micron tissue sections stained with H&E were reviewed by a Histopathologist (Dr 
Samuel Boros, IQ Pathology West End Australia) for confirmation of the diagnosis and 
presence of SCC tumour within the tissue sections. Dr Boros assessed the differentiation of 
the tumours across different mice passages in a blinded manner. He also assessed the 
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amounts of SCC present in the slide as well as the degree of necrosis of the tumour across 
different time passages.  
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2.3 Results 
In collaboration with the head and neck surgical teams at the Princess Alexandra Hospital, we 
developed a workflow where patients scheduled for surgical removal of head and neck SCC 
lesions were assed prior to surgery for suitability for participation in this study. I attended the 
pre-theatre surgical bay to examine the patient and if necessary consult with the treating 
surgeon. Patients who were deemed suitable were consented for participation in research 
(HREC 13/QPAH/406). A 3-4 mm punch biopsy from the resected SCC specimen was 
collected fresh. To date, 47 specimens have been collected between April 2015 to January 
2017 (Table 3). The majority of these patients have been >50 yrs and male with 79% being 
either current or ex-smokers. Additionally, 79% of samples collected were primary tumours 
with a moderate differentiation (49%) histological subtype. 
Table 3: Demographics and tumour characteristics of the 47 tumours collect from 
patients operated at the Princess Alexandra (PA) Hospital from May 2015-January 2017 
 
Age (yrs) n (%) 
<50 3 (6) 
>50 44 (94) 
  
Gender  
Male 39 (83) 
Female 8 (17) 
  
Site  
Tongue 10 (21) 
Parotid 6 (13) 
Oral Cavity 13 (28) 
Naso/Oropharynx 12 (25) 
Skin 6 (13) 
  
Primary 37 (79) 
Metastasis 5 (10.5) 
Recurrence 5 (10.5) 
  
Smoking status  
Ex-smoker 14 (30) 
Current smoker 23 (49) 
Non-smoker 10 (21) 
  
Histological Subtype  
Well Differentiated 11 (23) 
Moderately Differentiated 23 (49) 
Poorly Differentiated 8 (17) 
Not stated 5 (11) 
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2.3.1 Establishing an aseptic technique for specimen preparation 
The skin and oral cavity is colonized with a large burden of commensal bacteria.  Thus, 
despite the use of aseptic techniques it is assumed that biopsy samples will not be sterile. We 
observed that biopsy samples showed obvious visual signs of fungal and bacterial 
contamination if stored in media prior to implantation. Accordingly, we wanted to confirm 
that we were able to effectively decontaminate samples prior to implantation to minimize the 
possibility of infection in the immunocompromised mice. To test this three different samples 
were incubated in media after chlorhexidine pre-treatment with and without antibiotics 
overnight through a series of three passages (Figure 4). The media from each culture was 
collected after 24 hours incubation at 37 oC at each stage of passage to see how effective our 
decontamination protocol was.  
     Passage 1                Passage 2      Passage 3 
                                                             37 degrees o/n                                    37 degrees o/n 
                                                                                               
                                           supernatant passage 1 + media with Abx          supernatant passage 2 + media with Abx   
 
                                        37 degrees o/n                                    37 degrees o/n 
                                                                                                      
                                supernatant passage 1 + media w/o Abx          supernatant passage 2 + media w/o Abx           
Figure 4: Flowchart showing the passage of tissue three times in media with and without 
antibiotics (o/n is overnight, w/o is without, Abx is antibiotics)    
 
Polymerase chain reaction (PCR) was used to detect bacteria-specific sequences to see if 
there was a difference in the burden of bacteria in samples that were treated with and without 
antibiotics. The 16S rRNA gene sequence is a widely used marker gene for estimating 
bacterial contamination because “it contains both highly conserved regions for primer design 
and hypervariable regions to identify phylogenetic characteristics of microorganisms [57].” 
Yang et al (2016) showed that the V4-V6 was the most reliable region to represent the full-
length 16S rRNA sequences in the phylogenetic analysis of most bacterial phyla [58]. 
Accordingly a Bacterial PCR was set up to detect the hypervariable region of V4 bacterial 
ribosome was performed in two oropharyngeal samples. 
Tissue + 
media with 
Abx  
wwith Abx
 Tissue +       
media w/o 
Abx 
25 
 
 
The results clearly show that the original biopsies are contaminated and that treatment of 
oropharyngeal samples with chlorhexidine is not sufficient to remove the bacteria from the 
sample (Figure 5 “without antibiotic” lanes).  However, incubation with the antibiotic 
“cocktail” of penicillin, 
gentamicin, streptomycin and 
amphotericin B is clearly 
effective in reducing the 
bacterial burden of the samples, 
as the hypervariable region of 
V4 bacterial ribosome was not 
detected in the laryngeal and 
alveolar margin SCC samples 
passaged with this antibiotic 
regime (Figures 5). Only a low 
level of this hypervariable region 
was seen in the tongue SCC after 
the first passage with no 
detection in subsequent passages 
using these antibiotics (Figure 
6). Indeed, no infection has been 
detected in any of the 36 PDX 
mice implanted to date. These 
data show that surgical decontamination of the specimen with chlorhexidine is not sufficient 
to remove commensals in the mouth and that overnight incubation with a cocktail of 
antibiotics is necessary to decontaminate the specimen prior to implantation.  
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Figure 5: PCR of Laryngeal SCC show bacterial bands in 
the 3 passages without antibiotics indicative of 
contamination with no detectable band for the 3 passages 
treated with antibiotics. Yersinia is a positive control, w/o 
without, Abx is antibiotics, NT is non template control 
(sterile water) 
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2.3.2Implantation success and PDX growth rates  
To date, 47 biopsy samples have been implanted into NSG mice. The tissue was embedded in 
matrigel and implanted subcutaneously into the dorsal nape of neck of mice. Mice were 
monitored twice weekly for signs of tumour growth. Macroscopic tumours, as assessed 
histologically by Dr Sam Boros were detectable and measurable in 15 of the 47 mice 
corresponding to a 32% PDX success rate for implantation. Figure 7 shows the time to 
development of tumours in these PDX mice ranges from 6 – 44 weeks to develop in the mice. 
Engraftment was more successful when samples were derived from SCC that were poorly 
differentiated or were derived from patients with nodal disease. PDX tumours have been 
generated from poorly (50% of parental tumours collected) or moderately differentiated (22% 
of parental tumours collected) tumour samples. No PDX tumours have developed in any of the 
mice implanted with the 11 well differentiated tumours.  
Other than the obvious lack of growth of well differentiated tumours all other tumours, once 
established, grow with similar growth kinetics (Table 4). There was no obvious relationship 
between time to overt tumour growth and histopathological subtype with the exception of the 
poorly differentiated metastatic SCC which for the most part grew the quickest of all the 
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Figure 6: PCR of a Tongue SCC show bacterial bands in the 3 
passages without antibiotics indicative of contamination with no 
detectable band for the 3 passages treated with antibiotics. Yersinia 
is a positive control, w/o is without, Abx is antibiotics, NTC is no 
temple control (sterile water) 
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tumours as evidenced by the steepness of the slope of the growth timeline (Figure 7 and Table 
4).   These data indicate that PDX tumours establish in approximately 32% of cases and 
display a highly variable time to the initiation of a growing tumour. This study highlights the 
challenges of developing PDX of head and neck cancer. The engraftment rate was low but 
may be improved by selecting patients with metastatic disease and poorly differentiated 
tumours 
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Figure 7: PDX tumours implanted in mice had a variable time to onset. Tumour diameter 
along its longest axis was measured weekly in the nine PDX mice that have grown tumours 
from May 2015- August 2016 (PD-poorly differentiated in red, MD- moderately 
differentiated in green. Five of the mice were culled before they reached full size mainly due 
to the mice being sick or tumours being ulcerated or necrotic 
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Table 4: Slope of linear portion of the growth curve was calculated for PDX tumours  
(change in tumour diameter/change in time) for the 9 tumour samples that have 
reached 10mm diameter. This gives an indication of the speed of growth of each of the 
10 tumours according to histological subtype  
Histological Type Slope of Line (mm change in 
diameter/week +/- SEM) 
MD piriform fossa SCC 1.559 ± 0.1206 
MD ventral tongue SCC 0.6245 ± 0.04916 
MD supraglottic SCC 0.5073 ± 0.006096 
MD oropharyngeal SCC 0.8838 ± 0.07965 
MD hypopharyngeal SCC 0.977 ± 0.257 
MD retromolar trigone SCC 0.7124 ± 0.04175 
MD maxillary SCC  0.4946 ± 0.02899 
PD metastatic neck SCC 1.913 ± 0.3006 
PD lateral tongue SCC 1.941 ± 0.1582 
PD parotid SCC 1.429 ± 0.2274 
 
2.3.3 Post implantation tumour events 
It was noted that in the immediate period post-implantation that tumours appear to involute as 
none of them were physically palpable after two weeks.  Therefore, we wished to determine 
the events that were associated with tumour involution prior to future tumour development 
many months post implantation. It is well described that PDX tumours enter a period of 
indolent growth [23] however, we noted that tumours actually involuted suggesting it was not 
simply dormancy but rather there was a selection process leading to the loss of the implanted 
tumour tissue. Therefore, we used a combination of histopathological assessment and 
immunohistochemical marker analysis to profile the fate of human tumour cells in the 
immediate period post-implantation.  Nine separate tumour biopsy samples were implanted 
into 9 separate mice and the mice were euthanized and tumours collected from the surgical 
site at 4, 7 and 14 days post implantation. The histological examination of the tumours were 
all confirmed to contain tumour at the time of implantation.   
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H & E stained sections of 3 tumours recovered at 0, 4, 7 and 14 days were assessed by a 
consultant Histopathologist (Dr Samuel Boros). He determined that at 4 days post-implanta t ion  
50% of the section was described as necrotic as evidence by dead cells seen microscopica l ly 
(Figures 8A & B).  By day 7 this had increased to 90% necrosis (Figures 8C & D).  Finally by 
day 14 virtually no SCC cells were visible by histopathological assessment of any of the 
implanted biopsy specimens (Figure 8E). These data suggest that in the 14 day period following 
implantation that there is a profound loss of SCC cells (Figure 9).   
Figure 8: Histopathological assessment of implanted tumour specimens 4, 7 and 14 days 
post implantation. A) Low power and B) 100x magnification at 4 days post implantation 
with arrow indicating desmosomes and asterix indicating prominent nuclei of SCC. 50% of 
the tumour was quantified as necrotic at this time point. C) Low power and D) 100x 
magnification of tumour sample at 1 week post implantation was quantified as being 90% 
necrotic with only small amounts of the original SCC present on the periphery of the sample. 
E) 14 days post implantation- no SCC cells were seen 2 weeks after implantation with 
infiltrative cells present on the periphery of the tissue sample .   
A B 
C D 
E 
100 µm 
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Figure 9: The Mean ± SEM percentage of necrotic tissue as assessed by Dr Boros for each of 
the three mice at that day post implantation (three mice per day post implantation). These 
results show increased necrosis of tumour tissue with increasing time post implantation. 
These findings were validated by examining the expression of the human epithelial-specific 
marker, cytokeratin 5/6 in the same tumour samples.  Of the 3 specimens examined at day 4 
post implantation, there was evidence of large nests of SCC cells which were positive for the 
human epithelium-specific marker, CK5/6 (Figure 10A) with approximately 60% of the 
IgG Control 
 A 
    
  
Figure 10: Immunohistochemical staining of 3 different implanted HNSCC tumors at 4, 
7 and 14 days post implantation with cytokeratin 5/6 at 20X magnification. A) 4 days after 
implantation B) 7 days after implantation C) 14 days after implantation. Slides were 
deparaffinized, blocked and stained with antibodies against cytokeratin 5/6 and IgG. Protein 
expression pattern was visualized using Horseradish Peroxidase-conjugated secondary 
antibodies. Hematoxylin was used to visualize cellular structure.  
 B  C 
100 µm 
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surface area of the slide staining for CK 5/6 across 3 different mice. At 7 days post 
implantation (Figure 10 B), the number of CK5/6 positive SCC nests decreased to 
approximately 50% (Figure 10) and at 14 days post implantation, only a small cluster of cells 
remained at the periphery (Figure 10 C). These data clearly show that there is a profound loss 
of tumour cells at14 days post-implantation.  The cause of this loss could be due to cell death, 
tumour cell migration or immune cell clearance of tumour tissue but is clearly not due to 
dormancy. 
To determine whether the loss of SCC cells could be attributed to post-implantation apoptosis 
we quantitated cleaved caspase 3 staining in the tumours at 4 and 7 days post-implantation 
(Figure  11).  Figure 11 a-b shows an increase in the staining of cleaved caspase 3 on day 7 as 
compared to day 4. These findings provide independent validation of the histological necrosis 
evident at 4 and 7 days post implantation as assessed by Dr Samuel Boros (Figures 8a-e). 
This data were consistent across the majority of implanted human tumour biopsy SCC 
samples examined (Figure 9).   These data clearly show that the profound loss of tumour bulk 
in the 14 days post-implantation is accompanied by profound tumour cell death as evidenced 
by two independent markers.  These findings have not been reported for HNSCC PDX 
before. 
 
We assessed whether loss of proliferation may also contribute to the implanted tumour’s  
growth in the immediate period post-implantation. The percentage of cells that stained 
positive for BrdU at days 4 and 7 from 3 different SCC samples was used to assess cell 
proliferation in these tumours (Figures 12a-b). While approximately 50% of the SCC tumour 
at day 4 across the 3 different samples stained positive for BrdU there were very few (10%) 
 
 
  
Figure 11: Immunohistochemistry staining of implanted HNSCC tumors at 4 and 7 days 
post implantation with cleaved caspase III at 20X magnification A) 4 days after implantation 
B) 7 days after implantation. Slides were deparaffinized, blocked and stained with antibodies 
against cleaved caspase III and IgG. Protein expression pattern was visualized using Horseradish 
Peroxidase-conjugated secondary antibodies. Hematoxylin was used to visualize nuclei.  
IgG Control A B 
100 µm 
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BrdU positive cells present within the SCC tumour at 7 days post implantation (Figures 12 & 
13). These data show that during the 7 day period following implantation proliferation is not 
sufficient to offset the profound tumour cell death that occurs.  Hence tumour involution 
occurs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Immunohistochemistry staining of implanted HNSCC tumors at 4 and 7 days post 
implantation with Bromodeoxyuridine (BrdU) at 20X magnification A) 4 days after 
implantation B) 7 days after implantation. Slides were deparaffinized, blocked and stained with 
antibodies against BrdU and IgG. Protein expression pattern was visualized using Horseradish 
Peroxidase-conjugated secondary antibodies. Hematoxylin was used to visualize nuclei.  
IgG Control A  B 
100 µm 
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I then used immunofloresence to determine the percent of human tissue within the tumour 
samples that were undergoing cell proliferation and cell death. Interestingly, co-localisation   
using the  molecular 
probes cytokeratin 5/6 
and BrdU showed that 
although there were fewer 
human tumour cells, there 
was a markedly higher 
proliferation index in the  
tumours cells at day 14 
compared to day 4 (Figure 
14). Similarly, the 
percentage of cleaved 
caspase 3 cells within the 
cytokeratin 5/6 positive 
tumour cells decreased 
with time after 
implantation (Figure 15) with the number of cleaves caspase 3 positive cells decreasing from 
~20% at day 3 to ~3% at day 14 (Figure 16). These findings indicate that although there is an 
overall decrease in proliferation and increase in cell death that causes the large scale loss of 
viable tumour cells this is accompanied by the emergence of a small population of cells with 
the tumour that are  undergoing increased proliferation with decreasing apoptosis.  
Figure 13: Percentage of BrdU nuclei positive cells across 5 
random fields per slide for 3 different mice at day 4 and day 7 
post implantation. Each colour denotes 5 random fields per 
individual mouse per time course. The number of BrdU positive 
cells were measured using a cell counter on image J (mean + SE) 
D
a
y
 4
D
a
y
 7
0
2 0
4 0
6 0
F ig u re  1 3  %  o f  B rd U  p o s it iv e  c e lls  in  6  m ic e  d a y s
p o s t  im p la n ta t io n
D a y s  P o s t im p la n ta tio n
%
 B
r
d
U
 p
o
s
it
iv
e
 c
e
ll
s
34 
 
 
Figure 14: Co-localisation of molecular probes cytokeratin 5/6 and BrdU detected by 
immunofluorescence in tumours 4,7 and 14 days after implantation. DAPI counterstained 
nuclei in blue and the merge columns display cytokeratin 5/6 in green and BrdU in red. 
Images are representation of 3 biological replicates per time course.  
Figure 15: Co-localisation of molecular probes cytokeratin 5/6 and cleaved caspase 3 
detected by immunofluorescence in tumours 4.7 and 14 days after implantation. DAPI 
counterstained nuclei in blue and the merge columns display cytokeratin 5/6 in green and 
cleaved caspase in red. Images are representative of 3 biological replicates per time 
course.  
1000 µm 
1000 µm 
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Figure 16: Quantitative analysis of apoptotic (cleaved caspase 3) 
and proliferation (BrdU) markers in the days post-implantation.  
Data presented as percentage of positive cells presented as mean 
± SEM of 3 tumours at that day post transplantation  
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2.4 Discussion 
 
In this chapter I report on the establishment, and characterization of, a technique for 
generating first generation HNSCC PDX in mice. In this regard, I have made a number of 
important observations about the events in the immediate period post-implantation.  These 
observations have not been reported before and have considerable relevance to determining 
whether PDX models of HNSCC can be relied upon to recapitulate the human donor tumour 
in a mouse host. In particular, I noted that, i) approximately 40% of HNSCC samples will 
generate PDX tumours which take between 6 and 44 weeks to develop, ii) well differentiated 
HNSCC do not form PDX tumours and, iii) there is a profound loss of tumour cells in the 14 
day period following implantation that is accompanied by an increase in apoptosis.  These 
observations suggest that there is a massive selection pressure placed on PDX tumours 
following implantation which may have an impact on the complexity of the PDX tumours 
generated.    
 
2.4.1 HNSCC subtypes generate PDX tumours with differing efficiencies. 
A significant observation of the present chapter are the observed differences in the ability of 
different subtypes of HNSCC to generate PDX tumours. The factors determining successful 
engraftment rate are incompletely understood, but from my data appear to correlate, to an 
extent, with histological subtype of the tumour with the highest success rate seen in poorly 
differentiated tumours. In contrast, I did not manage to generate a PDX tumour from any of 
the 11 well differentiated HNSCC implanted. Thus, tumours which display characteristics 
more closely resembling undifferentiated and uncommitted keratinocytes appear to engraft, 
survive and replicate more readily.  This may not be unexpected since these tumours are more 
pleomorphic and have more mitotic activity which suggests they may be able to adapt to the 
change in tumour environment from the human to the mouse. They are also the tumours that 
are more likely to metastasize suggesting they may already have an inherent ability to 
colonise tissue sites at a distance from their primary origin. These findings are consistent with 
those of Hidalgo et al (2014) who showed that more aggressive tumours have a higher rate of 
engraftment in the generation of PDX models [40]. These data suggest that not all subtypes of 
HNSCC may be able to be recapitulated in a PDX environment.   
The difference in ability of different HNSCC subtypes to generate PDX tumours may also 
suggest that they have different oncogenic drivers.  In this regard the oncogenic drivers could 
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be considered to be classical oncogenes (eg Ras) or tumour suppressors (eg p53) or perhaps 
pro-survival genes (eg AKT or Bcl-2) or finally immune suppressors (eg PD-L1).  Regardless 
of the mechanism, my data indicates that different subtypes of tumours have different driver 
events to one another.  If true, my data suggest, from a functional standpoint, that different 
targeted therapies may be effective against the different subtypes of HNSCC.  This differs to 
the current treatment which is essentially the same regardless of tumour type (eg carboplatin, 
taxanes, anti-EGFR antibodies or 5-fluorouracil). 
 
2.4.2 Implication of post-implantation cell death on the robustness of PDX 
models of HNSCC 
My data suggests that HNSCCs are subjected to a profound selection pressure when 
implanted into mice. The immunohistochemistry and histopathology results support the 
proposition that the resulting xenograft tumour may arise from a small percentage of the 
originating parental tumour cells. Indeed it would appear that the majority of SCC tumour 
undergoes progressive apoptosis with no visible tumour present histologically at 14 days post 
implantation. The loss of tumour tissue was accompanied by significant staining for the 
apoptosis marker, cleaved caspase 3. It was not evident in this study whether the massive 
debulking of the tumour was restricted to specific subclonal variants within the tumour or 
whether all tumour cells were similarly effected regardless of the their clonal/subclonal 
origins. This is important because if it is uniform then this would maintain the intratumoural 
genetic heterogeneity whereas if it did differ between subclonal variants then this would lead 
to reduced complexity and genetic heterogeneity in the developing PDX tumour.  This 
question will be specifically addressed in the next chapter.   
A previous study of the genetic diversity in serially passaged breast cancer tissue has shown 
that intratumoural genetic heterogeneity is reduced during serial passage [50]. This shows 
that passaging PDX tumours leads to a loss of diversity and a reduced resemblance to the 
tumour of origin.  My preliminary findings in this chapter clearly show that differences exist 
between different subtypes of HNSCC in their ability to generate tumours.  This clearly 
shows that not all tumour cells have the ability to survive in the host environment and 
generate PDX tumours.  This observation suggests that the selection pressure placed on the 
implanted tumours may selectively reduce the genetic complexity of the implanted tumour.  
This issue will be addressed in the next chapter. 
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2.4.3 PDX host represents a hostile tumour environment 
The massive debulking of the implanted tumours suggests that the environment in which they 
are placed may be considered hostile.  The contributors to this may be simply diffusional in 
so far as whilst a blood supply is establishing the tumour cells may die due to hypoxia or lack 
of nutritional supply.  To an extent this is supported by my observation that surviving tissue 
tended to be found on the periphery of the implanted tumour samples. Attempts to stain for 
CD31 were unsuccessful as no signal was detected despite numerous repeats done by myself 
and another member of my lab, and so we have been unable to address the question of 
angiogenesis specifically. However, it must also be considered that incompatibility between 
human and murine cytokines, hormones, growth factors  and their cognate receptor may not 
be conducive to the survival of the PDX tumour implant [59]. Either way, the data above are 
consistent with the host mouse providing a hostile environment for foreign tumour growth.  
These incompatibilities coupled with the introduction of foreign material (antigen) into the 
host may also induce an innate immune response.  NSG mice still have an innate immune 
system and we attempted to stain for murine macrophages in our samples with anti- F4/80 
antibody but it was unsuccessful.  Regardless of mechanism again, my data clearly shows that 
the majority of implanted tumour cells die within a short period following implanta tion.  The 
impact of this on the ability of the PDX tumours to retain the histopathological and molecular 
identity of the donor tumour will be addressed in the next chapter.  
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CHAPTER 3: Comparison of the histopathological and                  
genomic landscape during passage of PDX HNSCC 
tumours through mice 
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3.1 Introduction 
 
Advances in sequencing technology have led to a rapid expansion in our knowledge of the 
mutational landscape and oncogenic events associated with HNSCC.  In particular, HNSCC 
samples have been shown to harbor frequent mutations in PIK3CA, NOTCH1, CASP8 and  
MLL2 genes as well as loss of function deletion/mutations of tumour suppressor genes such as 
TP53 and CDKN2A in a majority of tumours [4]. In addition, sequencing data has shown that 
activation of known oncogenic signalling pathways such as, EGFR, HRAS and PI3K/AKT is 
altered in more than 60% of tumours[60].  It has also been established that more mutations 
occur in tumours from patients that smoke tobacco as compared to patients who do not [61]. 
Pickering et al (2013) showed that the majority of tumours had alterations in multiple targetable 
genes that could be exploited through the use of specific combination therapies rather than 
single agent therapy [60]. Indeed, Martincorena et al (2017) showed that positive selection on 
driver mutations that increased cell survival or proliferation outweighed any negative selection 
that may result in cell death or senescence during tumorigenesis [61]. This suggests that certain 
genetic alterations could be used as biomarkers for treatment selection which would expand 
the current armament of treatment modalities for head and neck SCC which in the past has 
comprised only of surgery, radiation and chemotherapy using cisplatin (and more recently 
taxanes). 
It has long been assumed that cancers occur following the accumulation of mutational events 
sufficient to cause the unregulated expansion of a transformed neoplastic cell type.  It has also, 
often been assumed that cancers of the same subtype may share a similar mutational signature 
in critical context-specific driver genes such that they could be targeted using a specific 
targeted therapy.  However, clinical evidence of response to targeted therapies would suggest 
that this is not the case.  Rather, clinical data would suggest that there is considerable 
phenotypic heterogeneity within tumours.   
Until recently, it was unclear whether HNSCC are initiated by a similar mutational event or 
whether each individual HNSCC is driven by its own unique signature of mutational events.  
Cancer has been shown to develop from the accumulation of somatic mutations and clonal 
selection that drive their development and proliferation [62]. A major finding of recent 
sequencing studies is that there may not be a single shared common driver event that 
characterises HNSCC.  Indeed, similar to breast cancer, there appear to be multiple driver 
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events that can contribute to oncogenesis and these differ between individual tumours.  As an 
example, a recent paper by Martincorena et al (2017) showed that only 5% of non-synonymous 
(coding) point mutations in head and neck cancers were predicted to be drivers [61]. More 
importantly, there is clear evidence for tumour evolution within the sequenced tumours which 
highlights the importance of intratumoural heterogeneity and clonal evolution in HNSCC.   
Given the evidence for clonal evolution and intra- / inter- tumoural heterogeneity it is important 
that when using models of HNSCC they faithfully recapitulate this phenomenon.  Thus, 
preserving intratumoural heterogeneity is essential if HNSCC PDX models are to be used in 
translational research [63]. Recent studies have suggested that head and neck PDX models are 
more similar to primary HNSCC than other types of tumours in terms of histological and 
molecular pathology [63,64]. This demonstrates the translational utility of PDX models as a 
means of studying tumour pathogenesis and guiding precision medicine in terms of assessing 
pharmacological response to different drug therapies [53]. This contrasts to immortalised 
HNSCC cells lines which show genetic alterations that differ from those seen in HNSCC 
tumours [65]. Established cell lines also show a homogenous morphology that differs markedly 
from that seen in human tumours [17]. Evidence from earlier studies suggests HNSCC PDX 
models share some characteristics with their tumour of origin with respect to histology, protein 
markers, promoter methylation and some gene expression [56].  However, Li et al (2014) 
recently showed that a subset of proteins/phosphoproteins were expressed at different levels in 
PDX models in comparison with the primary HNSCC tumour [65]. These contrasting data 
highlight the need for more detailed information about the growth, pathology and genetics of 
HNSCC tissue in a PDX setting.  In particular, there is a paucity of studies that examine clonal 
evolution within an HNSCC specimen as it is passaged through mice. Indeed, there is limited 
data on clonal evolution within primary HNSCC samples per se. In this regard clonal evolution 
is an attribute that can be exploited to validate whether the PDX tumours “drift” genomica lly 
during passage through mice. Clonal evolution can also be examined to determine if the 
evolutionary pressures and behaviour of PDX HNSCCs is similar to that of primary HNSCC 
specimens.  This is an important issue since knowing the actionable mutational events is likely 
to be used to guide treatment regimes in cancer patients in the future.   Thus characterising and 
mapping the mutational events is of considerable importance in establishing PDX models as 
clinically-relevant models of HNSCC. Also of importance is knowing whether the biologica l 
behaviour (clonal evolution) of the PDX mimics that seen in the patient samples.  In this chapter 
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I will use next generation sequencing and histopathology to assess the similarities and 
differences between the tumour of origin and 1st generation PDX tumours.   
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3.2 Materials and Methods 
 
3.2.1 Patient Tumour Engraftment into mice 
We transplanted 47 human HNSCC tumours directly into the mice using the methods described 
in chapter 2. Those that engrafted are referred to as first generation PDX tumours.  Once these 
tumours reached a volume of 1 cm3 the mice were sacrificed and the tumours excised.  Excised 
tumours were photographed and then carefully dissected into quadrants and each quadrant 
further dissected into 4 equal pieces and each piece implanted into NSG mice as described in 
Chapter 2 (Figure 17).  In this way, we could map the location of the second generation PDX 
tumours to the precise location they were derived from in the first generation tumour.   
 
3.2.2 Histologic Characterization 
Tumour tissues from parental and PDX models were fixed in formalin, paraffin-embedded and 
stained with hematoxylin and eosin. The tumours were examined in a double blinded manner 
by light microscopy by an Anatomical Pathologist (Dr Samuel Boras) who evaluated the 
tumours for the degree of differentiation (ie formation of keratin, cytological features and 
growth patterns). He gave a histopathological diagnosis and summary of each of the tumour 
samples from the patient sample, 1st generation PDX sample and 2nd generation PDX samples.  
 
3.2.3 Genomics 
3.2.3.1 Sample Preparation 
Nine of the 15 passaged parental tumours engrafted in the first generation mice.  A third of the 
original primary tumours was kept in 1 ml of RNlater solution (Ambion). A third was kept for 
H& E staining and the remaining third passaged through a first generation mice. The mice were 
sacrificed when they reached a tumour burden of ~1 cm3 where the tumour was split into four 
quadrants (Figure 17) and 
kept in 1 ml of RNlateral 
solution. The DNA was 
purified from the tissues 
using the QIAap DNA Mini 
Kit (Qiagen, Hilden 
Germany) according to the 
manufacturer’s protocol.  
RNA Later 
RNA Later 
RNA Later 
RNA Later 
Figure 17- Division of first generation tumour into four quadrants 
before sequencing to ascertain if there was evidence of clonal 
variation between different quadrants of the tumour 
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3.2.3.2 Sequencing data analysis 
The TEQC program was used to compute quality control measures such as specificity, coverage 
and sensitivity. Around 65-70% of reads mapped on targets with an average coverage ranging 
from 389- to 1332- fold. The coverage per probe was n=1130 and average coverage per gene 
n=46. 
Agilent Sure Select XT2 custom 1kb-499kb Next Seq 500 program was used to analyse the 
DNA using 2x75 bp paired end. Pyclone was used covering mutations with more than 50 reads. 
Table 5 is a list of the captured genes used in the agilent design.  
The reads were mapped to a concatenated human (hg19) and mouse (mm9) genome with 
Novoalign v3.02.08 (Novocraft, Selangor Malaysia), duplicates reads were removed using 
Picard v1.131, indel realignment and base quality score recalibration were applied using GATK 
v3.4 [66]. We subsequently filtered the reads mapping to the human genome.  The mutations 
(Single Nucleotide Variants and small indels) were called by the software MuTect2 v3.6 [67]. 
SnpEff v4.1 [68] was used to annotate and predict the effect of the variants using Ensembl 
annotation (GRCh37, release75). The mutations present in the Genome Aggregation database 
[69] at a frequency more than 1% were discarded (NFE or Non-Finnish European was used as 
background population).  
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Table 5: Captured genes represented on the agilent platform 
 
  
Gene Lenth mRNA 
AJUBA 
CASP8 
CCND1 
CDKN2A 
CDKN2B 
CRM1 
DICER1 
DDR2 
E2F1 
E2F7 
EGFR 
EZH2 
FAT1 
FAT3 
FBXW7 
FGFR1 
FGFR2 
FGFR3 
FLG2 
HRAS 
IRF6 
JMJD3 
KMT2D 
MLL 
MLL3 
NSD1 
KNSTRN 
NOTCH1 
NOTCH2 
NOTCH3 
NOTCH4 
PCLO 
PIK3CA 
PRDM9 
RIMS2 
RB1 
SYNE1 
SYNE2 
TP53 
TOP2B 
TP63 
 
2616 
4778 
4304 
1235 
4001 
4148 
10206 
6265 
2722 
5742 
5616 
2723 
14811 
19048 
3970 
5917 
4654 
4310 
11728 
1300 
4256 
7706 
20000 
89753 
16872 
12000 
2039 
9322 
11474 
13231 
4456 
20288 
9104 
1155 
6797 
4722 
27439 
3985 
3000 
5360 
5269 
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3.3 Results 
3.3.1 Histopathological analysis of SCC after mice passaging 
The H& E slides of all the first/second generation tumours were examined by an Anatomica l 
Pathologist and a histopathology report provided.  This was done in a double blind fashion.  
The identity of the samples were re-identified by us and the reports used to determine if the 
histopathological characteristics of the nine tumours remained the same across different 
passages (Figures 18a-i). Representative images of each of the nine tumours and their 1st and 
2nd generation PDX samples are presented below (Fig 18 going from left to right respective ly).   
Figure 18a: Histopathology of the Primary Piriform fossa SCC (A) and the samples taken after 
passage through the first generation PDX mouse (B) and a representative tumour from a second 
generation PDX mouse (C).  All samples shown at 40X magnification following H & E staining.   
Figure 18b: Histopathology of the Primary Ventral Tongue SCC (A) and the samples taken 
after passage through the first generation PDX mouse (B) and a representative tumour from a 
second generation PDX mouse (C).  All samples shown at 40X magnification following H & E 
staining.  
Figure 18c: Histopathology of the Primary Supraglottic SCC (A) and the samples taken after 
passage through the frist generation PDX mouse (B) and a representative tumour from a 
second generation PDX mouse (C).  All samples shown at 40X magnification following H & E 
staining.  
100 µm 
100 µm 
100 µm 
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Figure 18d: Histopathology of the Primary Oropharyngeal SCC (A) and the samples taken 
after passage through the first generation PDX mouse (B) and a representative tumour from a 
second generation PDX mouse (C).  All samples shown at 40X magnification following H & E 
staining.  
Figure 18e: Histopathology of the Primary lateral tongue SCC (A) and the samples taken after 
passage through the first generation PDX mouse (B) and a representative tumour from a 
second generation PDX mouse (C).  All samples shown at 40X magnification following H & E 
staining.  
Figure 18f: Histopathology of the Primary Hypopharyngeal SCC (A) and the samples taken 
after passage through the first generation PDX mouse (B) and a representative tumour from a 
second generation PDX mouse (C).  All samples shown at 40X magnification following H & E 
staining.  
 
 
 
 
 
 
100 µm 
100 µm 
100 µm 
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Figure 18g: Histopathology of the Primary Parotid SCC (A) and the samples taken after 
passage through the first generation PDX mouse (B) and a representative tumour from a 
second generation PDX mouse (C).  All samples shown at 40X magnification following H & E 
staining.  
Figure 18h: Histopathology of the Primary Retromolar Trigone SCC (A) and the samples 
taken after passage through the first generation PDX mouse (B) and a representative tumour 
from a second generation PDX mouse (C).  All samples shown at 40X magnification following 
H & E staining.  
Figure 18i: Histopathology of the Primary Maxillary SCC (A) and the samples taken after 
passage through the first generation PDX mouse (B) and a representative tumour from a second 
generation PDX mouse (C).  All samples shown at 40X magnification following H & E staining.  
 
 
 
 
 
 
100 µm 
100 µm 
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A summary of the results of the histopathology are presented in Table 6.  It was assessed that 
tumours maintained the same degree of differentiation in seven of the nine tumours but with 
more homogeneity in successive generations when compared to the original parent tumour. The 
other two tumours showed a change in histology from moderately differentiated in the parental 
tumour to poorly differentiated once they were passaged through first generation mice (Table 
6 Shown in tan coloured text). These data are consistent with progression of the tumours in the 
two instances where the histopathology differed between parental and first generation PDX. 
Table 6: Histopathology across passages from parental tumour to first and second 
generation tumours in nine mice. 
Parental tumour First Generation Mouse Second Generation Mouse 
Moderately differentiated 
Piriform fossa SCC 
Moderately differentiated SCC Moderately differentiated SCC 
Moderately differentiated 
ventral tongue SCC 
Poorly differentiated SCC Poorly differentiated SCC 
Moderately differentiated 
supraglottic SCC 
Moderately differentiated SCC Moderately differentiated SCC 
Moderately differentiated 
oropharyngeal SCC 
Moderately differentiated SCC Moderately differentiated SCC 
Moderately differentiated 
lateral tongue SCC 
Moderately differentiated SCC Moderately differentiated SCC 
Poorly differentiated 
hypopharyngeal SCC 
Poorly differentiated SCC Poorly differentiated SCC 
Moderately differentiated 
parotid SCC 
Moderately differentiated SCC Moderately differentiated SCC 
Moderately differentiated 
retromolar trigone SCC 
Poorly differentiated SCC Poorly differentiated SCC 
Moderately differentiated 
maxillary SCC 
Moderately differentiated SCC Moderately differentiated SCC 
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3.3.3 Correlation between growth rates in first and second generation PDX 
tumours  
In Chapter 2 we had universally observed that average time to measurable engraftment in first 
generation PDX mice was considerably slower than the average observed time to measurable 
engraftment of the same tumour in second generation PDX mice.  Given the variable time to 
engraftment seen in the first generation PDX models described in Chapter 2, we wanted to see 
if there was a correlation between time to engraftment of individual tumours in first generation 
PDX mice and time to measurable engraftment of the same tumour when passaged into the 
second generation PDX mouse. My results show a strong correlation between the time to 
palpable tumour in the first generation and second generation tumours with R square value of  
0.987 (Figure 19). Additionally, we found that the time to palpable tumour was quicker for the 
1st generation than the 2nd generation tumour. This has important implications for the use of 
PDX tumours clinically. In particular, the prolonged time to growth of individual tumours in 
these mice models is a significant barrier to their use as “avatars” for determining appropriate  
treatment regimes for individual patients. Given the near linear relation between time to growth 
of tumours in the 
first and second 
generation tumours 
we can predict the 
approximate time 
to tumour 
formation in the 
second generation 
mouse thus giving 
us an accurate time 
frame to expect to 
treat mice bearing second generation tumours in PDX models of clinical drug trials. We can 
calculate that the time to formation of the tumour in the second generation mouse using the 
following equation: time to second generation tumour = 0.839 * X (time to palpable tumour in 
first generation mouse) - 3.521 (Table 7). 
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Figure 19: Relationship between time taken for tumours to be 
palpable in 1
st
 and 2
nd
 generation mice (R
2
 = 0.987  ; P <  0.0001) 
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Table 7: Predicted and actual time to palpable tumours in second generation mice using 
the linear regression equation in figure 19 (0.839 * X -  3.521) 
Time to Palpable tumour 
in first generation (weeks) 
Predicted Time to palpable 
tumour in second generation 
(weeks) 
Actual time to palpable 
tumour in second generation 
(weeks) 
16 9.903 8 
9 4.03 4 
17 10.742 11 
12 6.547 7 
19 12.42 12 
6 1.513 2 
21 14.098 15 
16 9.903 10 
35 25.844 26 
 
Similarly we looked at the rate of growth (slope of “linear” portion of growth curve) of first 
generation tumours in comparison to the second generation tumours. While the second 
generation PDX tumours tended to grow more quickly. A linear relationship between the rate 
of growth in the first 
and second 
generations (R 
squared 0.4988; P 
value 0.035) 
indicating that slow 
growing tumours in 
the first generation 
mice were also slow 
growing in the 
second generation 
mice and vice versa 
(Figure 20). This 
indicates that the 
ability to engraft and the rate of growth of individual tumours is an inherent property of the 
tumour of origin.  It also suggests that during establishment and passage of tumours in a PDX 
setting that there is little evidence for phenotypic drift/evolution of the tumours during this 
limited time in a PDX setting.  Using these data we have identified a reasonably accurate way 
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Figure 20: Correlation between rate of growth of first vs 
second generation tumours (R
2
 = 0.4988; P = 0.035) 
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of predicting the growth behaviour of second generation PDX tumours which will be helpful 
in planning experiments for drug screens. 
 
3.3.3 Validation of the Primary HNSCC sample against a known mutational 
database 
The histopathology and growth/engraftment characteristics of the parental, first generation and 
second generation PDX tumours appears to be stable (Chapter 2 and Table 6).  Given there is 
a literature on clonal evolution in tumours we wished to interrogate high depth sequencing 
information for a suite of HNSCC –associated genes to see whether the mutational landscape 
was also stable.  These analyses would also serve to independently validate the PDX model as 
a valid model of human HNSCC. We initially validated the mutations found in our primary 
SCC sample against known mutations found in tumours of the aerodigestive tract as recorded 
in the Cosmic database. We found three mutations in our primary SCC sample that 
corresponded with common mutations found within tumours of the aerodigestive tract (Table 
8).   
Table 8: Mutations found in the primary tumour that correspond to mutations found in HNSCC 
in the Cosmic database 
GENE MUTATION MUTATION 
TYPE 
IMPACT VAF Number in 
aerodigestive 
Tract (Cosmic) 
dbSNP 
NOTCH2 pC19W Missense Moderate 0.333 10 Rs11810554 
NOTCH2 pP6fs Frameshift 
deletion 
High 0.117 5 Rs372504208 
KMT2C pC988F Missense Moderate 0.686 20 Rs28522267 
KMT2C pY987H Missense Moderate 0.084 20 Rs183684706 
KMT2C pP986P Silent Low 0.695 1 Rs28439884 
KMT2C pR909K Missense Moderate 0.192 13 Rs199504848 
KMT2C pS902S Silent Low 0.338 1 Rs942922667 
KMT2C pR894Q Missense Moderate 0.113 1 Rs76844681 
KMT2C pE864G Missense Moderate 0.194 5 Rs4024420 
KMT2C pG845E Missense Moderate 0.066 7 Rs4024419 
KMT2C pS806S Silent Low 0.415 1 Rs3896406 
KMT2C pS793S Silent Low 0.071 1 Rs2537263 
KMT2C pS784S Silent Low 0.065 1 Rs2537264 
KMT2C pS772L Missense Moderate 0.088 22 Rs4024453 
KMT2C pT316S Missense Moderate 0.464 23 Rs10454320 
KMT2C pL291F Missense Moderate 0.068 23 Rs56850341 
TP53 pP72R Missense Moderate 0.986 1 Rs1042522 
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Figures 21A and 21B show a graphical representation of the location of various mutations 
found in the primary squamous cell tumour in the NOTCH 2 and KMT2C genes.  
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Figure 21A: Graphical representation of position of various mutations within the Notch 
2 gene of the primary HNSCC tumour one 
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Figure 21B: Graphical representation of position of various mutations within the KMT2C gene 
on the primary HNSCC tumour one 
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3.3.4 Comparison of the genomic landscape of Primary tumour vs first 
generation tumours  
There were a total of 39 genes sequenced in the primary tumour. Of these, 28 genes (72%) 
were found to be mutated in both the primary and first generation tumours. Figure 22 shows 
the different types of mutations found in each of the 28 genes in the primary tumour.  
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Figure 22: Graphical representation of the percentage of different types of mutations  
present within individual genes of the primary tumour 
 
Using these sequencing data I was able to ask whether there was evidence for clonal evolution 
within the four different quadrants of the first generation tumour by comparing the number of 
mutations per gene in the parental and first generation tumours. It appears that all four 
quadrants of the first generation tumour show a high proportion of genes with one mutation, 
with a relatively low percentage of mutated genes harbouring more than two mutations (Figure 
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23). These data suggest that the mutational landscape in the first generation PDX tumours is 
relatively stable when compared with the mutational landscape of the parental tumour from 
which they were derived. Interestingly, all four quadrants of the first generation tumour had a 
smaller number of mutations per gene in comparison to the primary tumour suggesting more 
heterogeneity in the parental tumour compared to their matched PDX tumours. 
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Figure 23: Comparison of number of mutations per gene and the corresponding percentage of genes 
that had that number of mutations in the primary and each of the four quadrants of the first generation 
tumour. Top right panel shows division of primary tumour into four separate quadrants with the colour 
of the graph corresponding to the primary tumour and each of the four quadrants 
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The genomic stability of the PDX model was determined by comparing the proportion of 
mutations that were conserved, lost or gained in each of the four quadrants of the first 
generation tumour in comparison to the primary parental tumour. There was a higher 
proportion of mutations that were conserved between the primary tumour and each of the four 
quadrants of the first generation tumour, as reflected by the cluster of mutations along the slope 
in Figure 24. The closer to the line the more conserved are the mutational events. Details of the 
specific genes gained and lost across passaging are detailed in Table 9 and 10 below. Of the 28 
mutations identified in the primary tumour, 66.7% were conserved in quadrant one of the first 
generation tumour with 33.3% lost. The majority of the mutations gained had a VAF <0.5 with 
Figure 24: Comparison of the Variant Allele Frequency (VAF) of tumour mutations gained, 
lost and conserved in each of the four quadrants of the first generation tumours vs the 
primary tumour 
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the exception of the splice mutation in SYNE2 which had variant allele frequent (VAF) of 0.909 
and thus having a high impact on the development of the tumour in this PDX model. 
In quadrant two there were 61% of mutations conserved and 39% mutations lost in the first 
generation tumour.  All of the mutations gained in quadrant two had a VAF <  0.5 and thus had 
a low to moderate effect of the subsequent development of the PDX tumour. In quadrant three 
of the first generation tumour, 57% of mutations were conserved with 43% mutations lost. 
Similarly, all mutations gained had VAF <0.5 having either a low or moderate impact with two 
of the mutations being modifiers and thus resulting in no amino acid change in the first 
generation tumour (Table 9). There were 59.5% conserved mutations and 40.5% lost mutatio ns 
in quadrant 4 of the first generation tumour. Like quadrant one, the majority of mutations 
gained had a VAF <0.5 with the exception of the splice mutation in SYNE2 which had a VAF 
of 0.923 and thus had a high impact on the evolution of this tumour in situ. These results would 
suggest that tumours remain relatively stable during passaging with a relative majority of the 
genomic landscape being conserved in the PDX model. 
 
3.3.4 Evidence of clonal evolution in PDX tumours in comparison to primary 
human tumours 
The majority of the mutations lost were lost in all four quadrants of the first generation tumour 
with the exception of the NOTCH 2 and KMT2C genes which showed loss of mutations in 
some but not all quadrants. The NOTCH 2 5’UTR variation was lost in quadrants two and four 
only but was only a modifier mutations so was probably not of functional significance (Table 
9). In contrast the KMT2C lost some mutations in all four quadrants with other mutations only 
being lost in one or three quadrants. Of the mutations lost, some were missense mutations 
which resulted in a change of amino acid that was of moderate functional impact. Consequently 
their loss would have been of moderate significance in the evolution of the tumour in the 
mouse. This finding of mutational loss in some, but not all, quadrants of the first generation 
tumour provides evidence of differential clonal evolution occurring in different quadrants of 
the PDX mouse model. These data also suggest that those mutations that are lost cannot be 
considered driver mutations and hence their contribution to oncogenesis would be negligible. 
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Table 9: Mutations lost in passaging from the primary tumour to first generation tumour 
(where blue = mutation lost in all four quadrants, green = mutation lost in three 
quadrants, orange = mutation lost in two quadrants and yellow = mutation lost in one 
quadrant)  
1st Generation  
Quadrant 
Gene Variant Classification Amino Acid 
Change 
Variant Allele 
Frequency (VAF) 
Impact 
Quadrant 1 FLG2 Missense Mutation S2310Y 0.005 Moderate 
Quadrant 1 FLG2 Silent  H2309H 0.004 Low 
Quadrant 1 FLG2 Missense Mutation G2308A 0.003 Moderate 
Quadrant 1 FLG2 Silent I2147I 0.009 Low 
Quadrant 1 FLG2 Missense Mutation I2147T 0.009 Moderate 
Quadrant 1 TP63 Missense Mutation S132I 0.022 Moderate 
Quadrant 1 TP63 Silent P528P 0.061 Low 
Quadrant 1 NOTCH4 Missense Mutation P1994S 0.013 Moderate 
Quadrant 1 KMT2C Intron - 0.015 Modifier 
Quadrant 1 KMT2C Intron - 0.046 Modifier 
Quadrant 1 KMT2C Intron - 0.043 Modifier 
Quadrant 1 KMT2C Splice Site - 0.256 Low 
Quadrant 1 SYNE2 Missense Mutation I132V 0.402 Moderate 
Quadrant 1 SYNE2 Splice Site - 0.26 Low 
Quadrant 1 DICER1 3’UTR - 0.492 Modifier 
Quadrant 2 NOTCH2 5’UTR - 0.286 Modifier 
Quadrant 2 FLG2 Missense Mutation S2310Y 0.005 Moderate 
Quadrant 2 FLG2 Silent  H2309H 0.004 Low 
Quadrant 2 FLG2 Missense Mutation G2308A 0.003 Moderate 
Quadrant 2 FLG2 Silent I2147I 0.009 Low 
Quadrant 2 FLG2 Missense Mutation I2147T 0.009 Moderate 
Quadrant 2 TP63 Missense Mutation S132I 0.022 Moderate 
Quadrant 2 TP63 Silent P528P 0.061 Low 
Quadrant 2 NOTCH4 Missense Mutation P1994S 0.013 Moderate 
Quadrant 2 KMT2C Intron - 0.015 Modifier 
Quadrant 2 KMT2C Silent E1226E 0.019 Low 
Quadrant 2 KMT2C Missense Mutation K822R 0.012 Moderate 
Quadrant 2 KMT2C Intron - 0.046 Modifier 
Quadrant 2 KMT2C Intron - 0.043 Modifier 
Quadrant 2 SYNE2 Missense Mutation I132V 0.402 Moderate 
Quadrant 2 SYNE2 Splice Site - 0.26 Low 
Quadrant 2 DICER1 3’UTR - 0.492 Modifier 
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Quadrant 3 FLG2 Missense Mutation S2310Y 0.005 Moderate 
Quadrant 3 FLG2 Silent  H2309H 0.004 Low 
Quadrant 3 FLG2 Missense Mutation G2308A 0.003 Moderate 
Quadrant 3 FLG2 Silent I2147I 0.009 Low 
Quadrant 3 FLG2 Missense Mutation I2147T 0.009 Moderate 
Quadrant 3 TP63 Missense Mutation S132I 0.022 Moderate 
Quadrant 3 TP63 Silent P528P 0.061 Low 
Quadrant 3 NOTCH4 Missense Mutation P1994S 0.013 Moderate 
Quadrant 3 KMT2C Intron - 0.015 Modifier 
Quadrant 3 KMT2C Intron - 0.301 Modifier 
Quadrant 3 KMT2C Intron - 0.373 Modifier 
Quadrant 3 KMT2C Missense Mutation K822R 0.012 Moderate 
Quadrant 3 KMT2C Missense Mutation T820I 0.035 Moderate 
Quadrant 3 KMT2C Intron - 0.046 Modifier 
Quadrant 3 KMT2C Intron - 0.043 Modifier 
Quadrant 3 KMT2C Splice Site - 0.256 Low 
Quadrant 3 SYNE2 Missense Mutation I132V 0.402 Moderate 
Quadrant 3 SYNE2 Splice Site - 0.26 Low 
Quadrant 3 DICER1 3’UTR - 0.492 Modifier 
Quadrant 4 NOTCH2 5’UTR - 0.286 Modifier 
Quadrant 4 FLG2 Missense Mutation S2310Y 0.005 Moderate 
Quadrant 4 FLG2 Silent  H2309H 0.004 Low 
Quadrant 4 FLG2 Missense Mutation G2308A 0.003 Moderate 
Quadrant 4 FLG2 Silent I2147I 0.009 Low 
Quadrant 4 FLG2 Missense Mutation I2147T 0.009 Moderate 
Quadrant 4 TP63 Missense Mutation S132I 0.022 Moderate 
Quadrant 4 TP63 Silent P528P 0.061 Low 
Quadrant 4 NOTCH4 Missense Mutation P1994S 0.013 Moderate 
Quadrant 4 KMT2C Intron - 0.015 Modifier 
Quadrant 4 KMT2C Missense Mutation K822R 0.012 Moderate 
Quadrant 4 KMT2C Intron - 0.046 Modifier 
Quadrant 4 KMT2C Intron - 0.043 Modifier 
Quadrant 4 KMT2C Splice Site - 0.256 Low 
Quadrant 4 SYNE2 Missense Mutation I132V 0.402 Moderate 
Quadrant 4 SYNE2 Splice Site - 0.26 Low 
Quadrant 4 DICER1 3’UTR - 0.492 Modifier 
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This concept of clonal evolution is given further credence when looking at the mutations gained 
across all four quadrants in the first generation mice (Table 10). Only one mutation in SYNE1 
gene was gained across all four quadrants while one mutation in the KMT2D mutation was 
gained across only two quadrants. The rest of the mutations that were gained were unique to 
one quadrant and were not seen across the other quadrants showing that different parts of the 
tumour undergo different clonal evolutionary paths. The majority of these mutations had 
variant allele frequencies (VAF<0.5), with the exception of SYNE2 gene, confirming that these 
mutations were late events in clonal evolution.  These data clearly show that within a limited 
number of replicative cycles within a single tumour we can identify the origins of new clonal 
variants within a tumour, some of which, may alter tumour biology.  It is also noteworthy, that 
the evidence for tumour evolution suggests that the passaged tumour was largely stable with 
only small deviations in mutational profile between the implanted tumour and the resulting 
PDX tumour in early passages. Figure 25 is a graphical representation of the mutations 
conserved, lost and gained in quadrant two and three of a single gene, KMT2C. This clearly 
shows that the majority of mutations were conserved with only three lost mutations and two 
gained mutations in the first generation tumour in comparison to the primary tumour. 
Table 10: Mutations gained in passaging from the primary tumour to first generation 
tumour (where blue = mutation gained in all four quadrants, orange = mutation gained 
in two quadrants and white = mutation gained in one quadrant) 
1st 
Generation 
Quadrant 
Start 
Position 
Gene Variant Classification Amino 
Acid  
Change 
Variant Allele 
Frequency 
(VAF) 
Impact 
Quadrant 1 189562104 TP63 Missense Mutation G139D 0.129 Moderate 
Quadrant 1 189562111 TP63 Silent  R141R 0.136 Low 
Quadrant 1 189562118 TP63 Missense Mutation A144T 0.071 Moderate 
Quadrant 1 152652200 SYNE1 Silent Q4540Q 0.313 Low 
Quadrant 1 151945051 KMT2C Missense Mutation I823N 0.003 Moderate 
Quadrant 1 49438155 KMT2D 5’Flank - 0.162 Modifier 
Quadrant 1 77417780 E2F7 3’UTR - 0.107 Modifier 
Quadrant 1 64460536 SYNE2 Splice Site - 0.909 High 
Quadrant 2 153332604 FBXW7 In Frame Deletion E117 0.015 Moderate 
Quadrant 2 152652200 SYNE1 Silent Q4540Q 0.512 Low 
Quadrant 2 151970855 KMT2C Missense Mutation T316S 0.01 Moderate 
Quadrant 2 151970858 KMT2C Missense Mutation G315D 0.01 Moderate 
Quadrant 3 152652200 SYNE1 Silent Q4540Q 0.464 Low 
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Quadrant 3 139390683 NOTCH1 Missesnse Mutation Q2503P 0.06 Moderate 
Quadrant 3 49438150 KMT2D 5’Flank - 0.148 Modifier 
Quadrant 3 49438155 KMT2D 5’Flank - 0.11 Modifier 
Quadrant 3 7752286 KDM6B Missense Mutation T894A 0.111 Moderate 
Quadrant 3 7752295 KDM6B Frame Shift Delection Q897fs 0.097 High 
Quadrant 4 152629772 SYNE1 Splice Site - 0.36 Low 
Quadrant 4 152652200 SYNE1 Silent Q4540Q 0.396 Low 
Quadrant 4 82784516 PCLO Missense Mutation P481A 0.094 Moderate 
Quadrant 4 49426645 KMT2D Missense Mutation L3948H 0.108 Moderate 
Quadrant 4 49446094 KMT2D Missense Mutation T458P 0.096 Moderate 
Quadrant 4 77417777 E2F7 3’UTR - 0.168 Modifier 
Quadrant 4 64460536 SYNE2 Splice Site - 0.923 High 
Quadrant 4 32273735 E2F1 Intro - 0.462 Modifier 
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Figure 25: Mutations conserved, gained and lost in the KMT2C gene from primary tumour in quadrants 
two and three of the first generation tumour 
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3.4 Discussion 
 
In this chapter I looked at the histological and genomic similarity between the parental tumour 
and its subsequent passage in the mice. The stability of xenograft models with passaging is 
crucial for establishing the robustness of a preclinical platform. My preliminary data shows 
that patient derived xenografts are a good model for HNSCC and show similarity in 
histopathology and phenotypic features (growth and implantation) between primary SCC 
tumours and their PDX derivative with a relatively high proportion of genomic mutations being 
conserved between the primary and first generation tumours.  
 
3.4.1 Phenotypic similarity of passaged PDX tumours to Primary human 
tumours 
My results showed that the PDX tumour maintained the same histological characteristic in 77% 
of cases when compared to the original patient tumour. Moreover, the histologica l 
characteristic remained unchanged in passaging from first to second generation mice across all 
nine samples. The progression observed in differentiation of the two PDX tumours that went 
from moderately differentiated in the parent tumour to poorly differentiated in the matched 
PDX may represent the lost human stroma causing the tumour to become more solid, more 
poorly differentiated and more homogeneous in successive passaging generations. This work 
highlights the conservation of the histology in PDX models in reflecting similar histologica l 
characteristics to the original patient tumour which adds further credence to their use in testing 
therapeutic agents for clinical trial.  
An important and novel observation made in this study was the highly conserved nature of 
growth and implantation.  My study showed that the ability to engraft and the growth rate of 
implanted tumours was unchanged between first and second generation PDX tumours.  This is 
significant for two reasons.  Firstly, it shows that the mechanisms involved in engraftment and 
growth are stable in early passages of tumours and hence shows that genes / effectors that drive 
these events are stable. This could have implications for our understanding of metastatic events 
since engraftment at a new site and growth are critical requirements for the establishment of 
metastatic foci.  The second significant implication of my study is the observation that we can 
predict with a high degree of accuracy the time to engraftment and tumour development based 
on the characteristics of the first generation PDX. This has important implications for the use 
of the second generation PDX tumours in drug screens or even if one considered their use as 
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patient tumour “avatars”. For example, it would allow us assess the suitability of using mouse 
‘avatars’ in individual tumours to determine tumour response to different drug therapies based 
on the time frame taken for that particular tumour to engraft and grow in the 1st generation 
mouse.  
3.4.2 Minimum genetic drift of PDX models occurs after passaging in mice  
Overall my data has shown a general concordance between the mutational landscape in the 
primary and matched PDX sample. The PDX samples had slightly decreased mutation rates 
(perhaps because of residual unfiltered germline variants in the primary tumour) but overall 
showed little divergence from the original patient tumour. These findings were further 
supported by the work of Goa et al (2017) in which they showed minimal genetic drift of PDX 
models after serial passaging [70]. Moreover, this modest level of genetic drift is entirely 
consistent with my observation for the stability of major phenotypic events such as engraftment 
and tumour growth. 
 
3.4.3 Evidence of clonal evolution in the development of new mutations by 
passing of tumours through mice 
There was a modest variation in mutational burden and mutational frequencies between 
spatially distinct quadrants within the first generation PDX tumours. Whilst overall, the 
passaged tumours appeared relatively stable there was some evidence for clonal evolution 
within a tumour which is consistent with the intra-tumoural heterogeneity previously described 
for HNSCC. The data from my study shows clear evidence of clonal evolution within spatially 
distinct quadrants of the tumour with all quadrants having gained a unique mutationa l 
signature. For example, a comparison of VAF for various gene mutations suggest that 
mutations are gained at various stages of tumour progression  with some mutations having a 
greater predicted impact on the development of the tumour in comparison to others. 
Specifically, mutations with low VAFs (eg VAF < 0.1) indicate the mutation occurs late in 
tumour evolution and thus these events are not considered oncogenic drivers.  However, these 
mutational events can lead to phenotypic modification that could enhance metastatic potential 
or drug resistance.  Eirew et al (2015) made similar findings with breast cancer PDX 
engraftment [71].  In particular, they showed that once established breast cancer PDX 
xenografts appeared to be relatively genetically stable [71]. Thus, while the genetic landscape 
is generally conserved in PDXs, mechanisms for both positive and negative clonal selection do 
exist.  
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Overall, my data suggests that PDX models relatively closely recapitulate the original parent 
tumour and thus represent a robust model in which to evaluate tumour biology and novel 
therapeutic agents.  
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CHAPTER 4: Use of the PDX model to test a novel drug    
combination in head and neck cancer samples 
 
 
Excerpts from this chapter have been included in the following publication:  Saenz-Ponce 
N, Pillay R, de Long LM, ,Kashyap T, Landesman Y, Hazar-Rethinam M, Boros S, Panizza 
B, Daelemans D, Jacquemyn M, Gannon OM, Saunders NA.  Targeting the XPO1-Dependent 
Nuclear Export of E2F7 Reverses Anthracycline resistance in Head and Neck Squamous Cell 
Carcinomas. Science Translational Medicine, 2018. 10: p1-12 [72]. (See Appendix) 
 
Figures 26 and 27 were derived from contributions from Ms Lilia Merida Delong and Ms 
Natalia Saenz-Ponce. Figures 28-30 were a collaboration between myself and Ms Saenz-
Ponce. I developed the patient derived xenotransplant models depicted in these graphs and 
figures. I monitored the mice regularly and recorded and then plotted the growth of the 
tumours on a weekly basis. Mice were sacrificed using CO2 gas once a tumour burden of 
1cm3 was reached. I harvested the tumours and prepared the samples for 
immunohistochemistry and H&E staining.  
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4.1 Introduction 
 
Despite advances in surgical technique and multimodal therapy, the overall 5 year survival of 
HNSCC has remained essentially unchanged over the last 30 years [64]. This is primarily due 
to the emergence of chemo-resistance resulting in poor survival of patients with advanced 
disease [62]. To date four drugs have been approved by the FDA for the systemic treatment of 
head and neck SCC (carboplatin, paclitaxel, 5-fluorouracil and cetuximab). None of these drugs 
are considered curative and none of these drugs substantially improve five year overall surviva l 
rates. However, they do improve progression free survival in most instances. The failure of 
these therapies to cure patients is primarily because HNSCC is a complex cancer characterised 
by a large number of gene expression changes and  considerable intra-tumoural heterogene ity 
(see previous Chapters).  These attributes result in aberrant cell behaviour and complex 
responses to drug therapies [4]. One of the genes most recently described is the E2F 
transcription factor family whose dysregulation has been shown to be an important driver in 
the development of  head and neck squamous cell carcinoma [73]. E2F transcription factors 
regulate the expression of genes that are important for cell cycle progression, differentiat ion, 
apoptosis and drug resistance [73]. Some E2F members have been implicated in the activation 
and promotion of tumour proliferation while others have been associated with inhibiting cell 
growth and repressing transcription [74]. Thus, some E2F family members may contribute to 
neoplastic transformation when they are deregulated. For example, E2F1 has been shown to 
regulate progression through checkpoints in the cell cycle, and has also been implicated as 
having tumour suppressive activity predominantly through its ability to induce apoptosis in 
lymphoid tissues [74]. Central to this chapter are earlier findings that E2F was directly 
responsible for doxorubicin resistance in SCC cells [74]. 
Doxorubicin is a well-known anticancer drug that induces cures in many cancer types but has 
limited activity in head and neck SCC patients [75]. However, recent preclinical studies have 
shown that doxorubicin resistance is an E2F-dependent phenomenon [76].  In this regard, my 
laboratory has shown that E2F1 is able to induce the expression of an enzyme called 
sphingosine kinase-1 (Sphk1) [77].  Sphk1 is a kinase responsible for converting sphingosine 
to S1P. It has been shown to influence proliferation, differentiation and apoptosis in 
keratinocytes and its expression has been shown to be significantly increased in a variety of 
squamous cell carcinomas [77]. In contrast, E2F7 represses expression of Sphk1.  Thus, the 
70 
 
relative abundance of E2F1 vs E2F7 determines whether a cancer cell expresses Sphk1 or 
not. Sphk1 is an enzyme that catalyses the production of the anti-apoptotic lipid, sphingosine-
1-phosphate (S1P). Previous work from my laboratory has established that the E2F-
dependent control of S1P is the main driver of doxorubicin resistance in HNSCC [77].    
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4.2 Results 
 
4.2.1 E2F7 mislocalization is a novel actionable pathology in HNSCC 
 
E2F1 and E2F7 have been shown to be highly expressed in patients with SCC [78]. Since E2F1 
and E2F7 are both mutually antagonistic it means that whatever controls the ratio of E2F1 to 
E2F7 within the nucleus will control doxorubicin sensitivity.  In this regard, we recently 
showed that there is selective relocation of E2F7 from the nucleus to the cytoplasm in greater 
than 80% of HNSCC (Figure 26A). This is in contrast to normal epidermal and mucosal 
keratinocytes where the localization of E2F7 is predominantly nuclear (Figure 26B).  Further 
analysis showed that the mislocalization of E2F7 in HNSCC was due to nuclear export of E2F7 
via the exportin 1 protein (XPO1). My laboratory showed that the selective inhibitor of nuclear 
export selinexor (selinexor; KPT-330) caused accumulation of E2F7 in the nucleus of 
established SCC cell lines (Figure 27).   
 
 
 
Figure 26: A) Tissue microarrays of normal epithelia and head and neck squamous cell carcinoma that were 
stained for E2F1 and E2F7. The expression of E2F7 was classified as nuclear if staining was detected only 
in the nucleus of the cells or nuclear/cytoplasmic (N/C) if staining was found in both the cytoplasm and 
nucleaus of the cells or just the cytoplasm B) Quantification of the number of normal epithelium and 
squamous cell carcinoma tissue microarrays with nuclear or nuclear/cytoplasmic E2F7 expression. 
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The efficacy of the doxorubicin + selinexor combination was tested in xenotransplant tumours 
using SCC cells in which E2F7 was mislocalised to the cytoplasm. Our results showed a 
significant reduction in tumour growth compared with the vehicle and single agent treatment 
groups (Figure 28). Additionally, the drug combination of doxorubicin and selinexor increased 
the expression of the apoptotic marker cleaved caspase 3 and reduced the expression of the 
proliferation marker Ki67 (Figure 29A). To add further credence to this result, immuno-
histochemical analysis showed that selinexor caused accumulation of E2F7 in the nucleus of 
both the SCC25 and Detroit cell line tumours (Figure 29B).  
 
Figure 27: Western blot (A) Quantitative analysis (B) of nuclear and cytoplasmic expression of E2F7 
in SCC25 cells treated with 1 µl/ml DMSO for 8 hours or 5 µl/ml of LP for 32 hours or 1 µM selinexor 
for 4 or 8 hours. Proteins were normalised to actin. (C) Changes in subcellular location of E2F7 after 
treatment with 1uM selinexor were confirmed by immunofluorescence  
B 
C 
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4.2.2 Use of PDX models to validate the use of drug combination therapy in 
HNSCC 
 
I generated three PDX models in order to validate the results seen in the SCC25 
xenotransplant cell line model. Three patient derived SCC samples were implanted into three 
NSG mice and their growth followed as per Chapter two. Each tumour was subsequently 
passaged into 16 NSG mice once the parent tumour had reached a size of ~10mm3. Once the 
second generation PDX tumour reached ~four mm in diameter, they were randomly assigned 
to four groups (control + three drug trial groups). Sufficient second generation PDX tumour 
bearing mice were generated in order to examine the effects of selinexor and doxorubicin 
both individually and as a drug combination using the same drug treatment regime used to 
treat the SCC25 xenotransplant models (Figure 30). Mice were treated twice per week for 
three weeks with i) 0.5mg/kg doxorubicin (Sigma-Aldrich), ii) 15mg/kg selinexor or iii) 
15mg/kg selinexor + 0.5mg/kg doxorubicin. Mice were monitored twice per week for 
changes in weight and tumour size. Animals were sacrificed at the end of the three-week 
period or if the tumour size reached 10mm in diameter. 
Figure 28: Xenotransplant model for SCC25 where mice were treated for 14 days with i) 
vehicle (0.6% plasdone PVP K-29/32 and 0.6% Poloxamer pluronic F-68), ii) 0.5mg/kg 
doxorubicin, iii) 15mg/kg selinexor, iv) 15mg/kg selinexor + 0.5 mg/kg doxorubicin. 
Mice were sacrificed 5 days following cessation of treatment or at attainment of an 
ethically-imposed threshold. Vales of the tumour growth curse are presented as mean ± 
SEM (n=4) 
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Immunohistochemistry was used to determine the subcellular location of E2F7 within each of 
these three tumours. Two of the three SCC samples displayed localisation of E2F7 to the 
cytoplasm (Figure 30) while one SCC tumour showed E2F7 expression that was localised to 
the nucleus (Figure 31). These particular PDX tumours grew at variable rates making it difficult 
to generate meaningful tumour growth rate curves across all treatment groups. However, figure 
29 shows that in the two PDX models where E2F7 was localised in the cytoplasm (A) there 
was a significant increase in cleave caspase 3 staining and reduced Ki67 staining compared to 
the agents when used alone (Bi-ii). These data prove the ability of the novel drug combination 
to enhance the cytotoxic response to doxorubicin in SCCs in which E2F7 is mislocalised to the 
cytoplasm. 
In contrast, the PDX tumour in which E2F7 was retained in the nucleus (Fig 31) showed 
sensitivity to doxorubicin alone and showed little improvement in sensitivity to selinexor alone 
or in combination with doxorubicin (Figure 31). This is to be expected since Fig 29 in Saenz-
Ponz et al, 2018 shows that the mislocalization of E2F7 is a driver of drug resistance and that 
Figure 30 Ai) Cytoplasmic E2F7 expression in parental tumour Bi-ii) Representative 
images and quantitative analysis of PDX resected tumours showing the expression of 
apoptosis (cleaved caspase3) and proliferation markers (Ki67). Quantitative analysis 
represents percentage of positive cells presented as mean ± SEM of at least four 
tumours.  
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reinstatement of nuclear E2F7 expression with selinexor [72] reinstates doxorubicin sensitivity. 
Thus, tumours in which E2F7 remains nuclear should be sensitive to the cytotoxic action of 
doxorubicin.  
 
 
 
 
 
 
 
 
        
 
 
 
 
 
 
 
Figure 31: Growth of PDX tumour after treatment with doxorubicin, selinexor or combination of the 
two. Growth is presented as mean ± SEM of at least four tumors (left panel). The right panel shows 
H&E and E2F7 staining in the parental tumor. 
100 µm 
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4.3 Discussion 
 
Approximately 85% of drugs with preclinical activity that enter oncology clinical trials fail to 
demonstrate the safety or efficacy required to gain regulatory approval [77]. Thus there is a 
need for better preclinical models that replicate the diversity of human tumour biology and thus 
can be used to assess the clinical potential of therapeutic drugs in a preclinical setting. By 
directly comparing drug responses in patients and their corresponding xenografts, Hidalgo et 
al (2014) showed that PDX models were able to faithfully recapitulate human tumour biology 
and predict patient drug response [40]. Indeed Goa et al (2005) generated ~1000 PDX models 
in order to perform a large-scale in vivo screen to model “inter-patient response heterogene ity 
with a one animal per model per treatment approach” [70]. They were able to successfully 
validate genetic hypotheses and in vitro biomarkers, and identify novel therapies that cell line 
models failed to capture. Indeed, when xenografts are treated with therapeutic agents used in 
patients with that same tumour, similar response rates are usually observed [79]. These data 
suggest that PDX models are good tools for testing the effectiveness of drug responses. In 
addition they may be useful in identifying relevant clinical mechanisms of resistance.   
Efforts to identify a subset of HNSCC patients who will respond to cytotoxic chemotherapy 
have been limited partly because of the use of immortalized cell lines and xenografts that have 
been derived from these cell lines for preclinical trials. Li et al (2016) showed that genetic 
alterations found in HNSCC tumours have little resemblance to the changes seen in 
immortalized HNSCC cell lines [79]. I have demonstrated in earlier chapters that PDX models 
are a robust model of head and neck SCC in terms of the concordance of histopathologica l 
differentiation in passaging as well as the conservation of genetic mutations found in both the 
original patient tumour and corresponding PDX model. These findings show that PDX’s are a 
credible platform in reflecting human tumours compared with xenografts that are derived from 
immortalized cell lines and are thus more useful tool for preclinical studies.  
A number of authors have noted the availability of PDX models allows for the generation of 
large numbers of mice bearing the same tumour which can be then used to conduct drug screens 
or clinical trials “by proxy” [35,38,45]. This particular attribute of PDX models may serve to 
expedite passage of preclinical leads through to clinical development by providing more robust 
mechanisms for identifying drugs with a high probability of efficacy in patient’s tumours.  In 
this chapter we exploited the strength of this system to determine the potential value of trialling 
a doxorubicin / selinexor drug combination in patients with relapsed HNSCC. 
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Through the use of 2 PDX tumours with cytoplasmic E2F7 and 1 PDX tumour with nuclear 
E2F7, I was able to show that the novel drug combination induced substantial sensitivity to 
doxorubicin in the in vivo setting. These findings showed that the mislocalization of E2F7 to 
the cytoplasm is driving doxorubicin resistance and that strategies to reinstate nuclear 
expression of E2F7 should reverse doxorubicin resistance.  Thus, tumours with pre-existing 
nuclear expression of E2F7 should be sensitive to doxorubicin whereas tumours in which 
E2F7is localized to the cytoplasm would benefit from a combination of doxorubicin plus a 
XPO1 inhibitor. This chapter demonstrate the potential clinical value of conducting a clinica l 
trial using selinexor + doxorubicin in relapsed SCC patients.  Significantly, this chapter also 
identifies a way to stratify patients for treatment.  In particular, the rare patients who have 
nuclear E2F7 may expect benefit following doxorubicin treatment alone whereas the 80% of 
patients with cytoplasmic E2F7 would be expected to derive benefit from a combination of 
selinexor + doxorubicin.  This hypothesis will be tested by conducting a clinical trial of “all 
comers” with relapsed SCC.  In this way we will be able to test the clinical effectiveness of the 
novel drug combination and determine whether the prior determination of the subcellular 
localization of E2F7 is a predictor of benefit.  Our data would suggest that a small fraction of 
patients (approx. 20%) may benefit from doxorubicin alone whereas the majority of patients 
(approx. 80%) will benefit from our novel drug combination.  
While it is clear from these results that the E2F1- dependent activation of the SPHK1/S1P axis 
suppresses the cytotoxic action of anthracyclines in SCC cells what is still unclear is the 
molecular basis for the mislocalization defect seen in HNSCC. Further experiments could be 
aimed at answering this question to see if this defect is attributable to mutations in the XPO 1 
protein itself or rather, and more likely, due to a pathology, driven posttranslationa l 
modification of the E2F7 protein or interacting partner protein. It is hoped that greater 
understanding of the factors that drive acquired and inherent resistance to chemotherapy will 
one day enable the successful use of combination therapies that will both reduce morbidity and 
mortality in HNSCC and help improve patient outcomes.  
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CHAPTER 5: General Discussion and Conclusions 
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The recent advent of patient derived xenotransplant models (PDX) has yielded some promising 
data in terms of their use as a preclinical model for testing chemotherapeutics. However, the 
central concern over PDXs is that they may fail to represent the phenotypic, transcriptiona l, 
genetic and immunologic characteristics of human tumours from which they are derived. This 
perceived weakness could limit their usefulness as a screening platform for new drug 
development. My thesis aimed to address some of these issues by:  
1. Developing a PDX model of head and neck SCC.  
2. Using histology and genomics to see how closely the PDX models resembled the 
primary SCC tumour from the patient.  
3. Using the PDX model to test the validity of a drug lead arising from my laboratory.  
 
Findings arising from my thesis report that i) HNSCC PDX tumours maintain their 
histopathological and tumourigenic properties in near term passages through 
immunocompromised mice, ii) near term passages of HNSCC PDX tumours maintain their 
mutational heritage with their tumour of origin and iii) I have validated the HNSCC PDX 
platform as a valid tool for screening new chemotherapeutic leads in HNSCC.  More 
specifically, my studies have provided detailed insight into PDX biology in general and 
HNSCC biology in particular. For example, I show a) that in the immediate period post-
implantation there is massive loss of tumour cell viability, b) that postimplantation atrophy 
impacts all clonal variants within the tumour since we provide sequencing data to validate the 
similarity between the tumour of origin and passage one and two PDX tumours, c) my genetic 
and histopathologic data shows the phenotype and genotype remains stable in near term 
passage.  Thus, my studies validate the use of PDX tumours as a robust model of human 
HNSCC in near term passage through mice.   
 
Based on analysis of a large number of tumour samples I established that engraftment occurred 
at a frequency of 43%.  Further analysis revealed that engraftment was restricted to moderately 
or poorly differentiated squamous cell tumours. This is consistent with an earlier study which 
showed greater success in implantation in tumours with higher malignancy potential [13]. 
Indeed other authors have found that engraftment correlated with less tumour differentiat ion, 
larger tumour sizes and tumours from patients with lymph node metastasis [80]. These data 
suggest that the efficiency with which a tumour engrafts in the PDX model is driven by the 
malignant behaviour of the tumour from which it was derived.  An additional important finding 
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in this study was the variable time to tumour growth following implantation.  This could take 
from a few weeks to a few months. Importantly, the time to the initiation of a palpable tumour 
was an inherent property of each tumour samples and was highly correlated between first and 
second passages of the PDX tumours.  Combined these data suggest that the ability to initia te 
a tumour and the rate at which the tumour develops are stable phenotypic traits that are inherent 
to the donor tumour sample.  
 
The data from the post-transplantation immunohistochemistry and immunofluorescence results  
clearly show that while a majority of the tumour implanted into the NSG mice involute and 
necrose, there is a residual population of cells that continue to proliferate. This suggest that 
there is significant atrophy of the implanted tumour tissue suggesting that only a very small 
fraction of cells survive. This may be due to selective loss of distinct clonal variants or could 
be due to widespread and non-selective loss of all clonal variants across the tumour.  Answering 
this question is important as it relates to how representative the PDX tumours are of the tumour 
of origin.  In this regard, my study indicates that PDX tumours retain the histologic 
characteristics of the parental tumour with 77% of the passaged PDX tumours having the same 
histopathological classification as the parental tumour. This is also entirely consistent with the 
mutational signatures I noted in the PDX tumour and tumour of origin. This is in keeping with 
previous findings which have shown that despite loss of the human stromal components upon 
engraftment, in nearly all cases the histology of the original parent tumour is similar to that of 
the matched PDX [56]. My data extends this to show that the basis for post-implanta t ion 
tumour atrophy is due to a generalized phenomenon rather than an inherent property of select 
clones to survive in the host.  Specifically, my data shows that there is a non-selective pressure 
placed on implanted tumours which is likely to be due to generalized events such as i) access 
to nutrients or O2 due to lack of vascularization or ii) immune cell removal such as by 
macrophages.  We didn’t note any increase in immune cell infiltration within the implanted 
tumours and did notice an increase in dead tumour cells which suggests the mechanism leading 
to tumour atrophy is simply lack of nutrients.  
 
As part of my study I conducted deep resequencing of genes commonly mutated in SCC. My 
analysis revealed that: a) the tumours remain relatively stable during generation of PDX 
tumours b) the genomic landscape is relatively stable and conserved and c) there is evidence 
for clonal evolution during tumour growth.  
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The preliminary findings in this study would suggest that PDX models relatively closely 
approximate primary SCC tumours both in terms of histology and genomic landscape. While 
the first generation PDX models show evidence of clonal evolution in terms of mutations both 
gained and lost, a vast majority of mutations were conserved across passaging. This suggests 
that despite the atrophy it is likely that there is minimal selection pressure for specific clonal 
variants within the implanted tumours as many features (genetic and phenotypic) are retained.  
 
While the clonal dynamics in the PDX model is similar to the originating tumour sample there 
is evidence of clonal evolution, albeit slowly. According to Cassidy et al, the “clonal dynamics 
derived from a tumour’s inherent heterogeneity are extremely complex and can play a key role 
in tumour progression and development” [81]. Further genomics studies would need to be 
conducted in order to ascertain whether changes in clonal prevalence are due to selection acting 
on pre-existing clones, rather than the generation of new clones as hypothesised by Aparicio et 
al [49]. Regardless of this, my study indicates that the PDX tumours represent a viable model 
to examine tumour biology and clonal evolution in an in vivo setting.  
 
In conclusion, even though tumour passaging into immunosuppressed mice have their 
limitations due to interspecies differences and variable time to engraftment, the results of this 
study show that PDX tumours are a relatively good representation of human HNSCC in which 
to conduct drug trials. However, even though the PDX tumours are relatively representative of 
the genomic architecture of human tumours they do not account for the heterogeneity seen in 
the tumour microenvironment. Thus, while PDX models have been used successfully in drug 
trials, stromal contributions to treatment responses may be under-represented [80].  
Nonetheless, this thesis shows that PDX models are capable of representing the complexity of 
human malignancy relatively well in terms of histopathology and the conservation of major 
genetic mutations found in both patient tumours and their corresponding PDX. These findings 
underpin the utility of PDX models in preclinical studies although more research is clearly 
needed to ascertain genomic drift and clonal dynamics with subsequent generations of tumour 
passaging as most drug trials are conducted on passaged tumours in second, third and fourth 
generation mice. This is important because it informs us about whether there are fundamenta l 
changes in the genotype and phenotype of malignant cells as they are generated and expanded 
in subsequent generations of mice. This information will better inform future studies of drug 
response and tumour biology in xenografts of head and neck cancer.  
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Abstract: Patient mortality rates have remained stubbornly high (40%) for the past 35 years 
in head and neck squamous cell carcinoma (HNSCC) due to inherent or acquired drug 
resistance. Thus, a critical issue in advanced SCC is to identify and target the mechanisms that 
contribute to therapy resistance.  In this study we report that the transcriptional inhibitor, 
E2F7, is mislocalized to the cytoplasm in > 80 % of human HNSCCs whilst the transcriptiona l 
activator,  
E2F1, retains localization to the nucleus in SCC. This leads to an imbalance in the control of 
E2F-dependent targets such as Sphk1 which is derepressed and drives resistance to 
anthracyclines in HNSCC. Specifically, we show that i) E2F7 is subject to XPO1-dependent 
nuclear export, ii) E2F7 is selectively mislocalized in the majority of SCC and multiple other 
tumor types, iii) mislocalization of E2F7 in HNSCC causes derepression of Sphk1 and drives 
anthracycline resistance and iv) anthracycline resistance can be reversed with a clinica lly 
available inhibitor of XPO1, selinexor,  in xenotransplant models of HNSCC. Thus, we have 
identified a strategy to repurpose anthracyclines for use in SCC. More generally, we provide 
a strategy to restore the balance of E2F1 (activator) and E2F7 (inhibitor) activity in cancer.    
  
Introduction  
Cancers arising from stratified squamous epithelial linings of the upper aerodigestive 
tract (Head and neck squamous cell carcinomas; HNSCC) are amongst the most common 
cancers globally and are caused by exposure to exogenous carcinogens such as tobacco smoke 
or excessive alcohol consumption and/or HPV infection (1,2). On a global scale, there are 
approximately 640,000 new cases of HNSCC diagnosed each year (3). Tumours which display 
no evidence of local, regional or distant spread are associated with high cure rates following 
surgery and/or radiation (4). Unfortunately, if the disease progresses and spreads to local, 
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regional and distant sites it is associated with an increasingly poor prognosis (4, 5).  In this 
context, treatment failure and patient mortality rates have remained stubbornly high (40%) for 
the past 35 years in HNSCC patients (3, 6).  This high mortality rate can be attributed to 
inherent or acquired resistance to chemotherapeutics used for HNSCC (e.g. platinum-based 
drugs, taxanes, EGFR-targeting therapeutic antibodies and 5-fluorouracil) (7-8). Thus, a 
critical issue in advanced SCC is to identify and target mechanisms that contribute to therapy 
resistance.    
  
Recent studies have shown that the E2F transcription factor family are key regula tors 
of chemotherapeutic sensitivity and in particular sensitivity to anthracyclines (9-10).  The E2F 
transcription factor family comprises 8 genes encoding 10 gene products which bind a 
consensus E2F response element (TTTSSCGC).  E2F family members are classified as 
transcriptional activators (E2F1, E2F2, and E2F3a) or inhibitors (E2F3b, E2F4, E2F5, E2F6, 
E2F7a, E2F7b, E2F8) and are important regulators of proliferation, differentiation, surviva l, 
apoptosis and DNA damage responses (11-14).  Significantly, many of the functions of the 
E2F family are contextspecific.  For example, E2F1 has been shown to have both tumor 
suppressive and oncogenic activity dependent upon the tissue context (15-17).  This apparent 
paradox most likely reflects the dominant activity of E2F1 in apoptosis or prolifera t ion 
depending upon the tissue context.   
  
In the context of unperturbed primary cultures of human keratinocytes derived from a 
stratified epithelium (epidermis), transient overexpression of E2F1 is sufficient to induce  
apoptosis which can be antagonized by transient overexpression of E2F7 (18, 19). However, 
in UV-irradiated mice, E2F1 displays anti-apoptotic and tumor suppressive properties whilst 
overexpression in a transgenic mouse model displays constitutively higher levels of apoptosis 
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and is oncogenic (20, 21). Recently, Thurlings et al showed that E2F1 ablation in the context 
of mouse keratinocytes was neither oncogenic nor tumor suppressive in a “skin painting” 
model of carcinogenesis (22).  However, E2F1 ablation combined with E2F7 and E2F8 
ablation resulted in increased tumor numbers suggesting a tumor suppressive role (22). These 
studies reinforce the critical importance of considering tissue and cellular context when 
interpreting E2F action. In the present study, we have focused on the mechanism of E2F-
dependent anthracycline resistance in the context of human HNSCC.     
  
 Earlier studies have shown that E2F regulates sensitivity to a number of conventiona l 
chemotherapeutics. In particular, E2F activity drives resistance to anthracyclines in SCC cell 
lines in vitro and in vivo (9, 10). This resistance is induced by the overexpression/activat ion 
of the inter-dependent sphingosine kinase-1 (Sphk1) and RACGAP1 pathways. Both 
RACGAP1 and Sphk1 are direct transcriptional targets of E2F7 and a causative contribution 
to anthracycline resistance was shown following genetic knockdown, overexpression and 
pharmacological inhibition in vitro and in vivo (9, 10). Moreover, interrogation of human 
tissue microarrays of HNSCC patients clearly showed that E2F7, Sphk1 and RACGAP1 were 
overexpressed in human SCC and were linked to a poor prognosis (12). Finally, it was shown 
that anthracycline resistance was driven by the increased levels of sphingosine-1-phospha te 
(S1P) that result from the conversion of sphingosine to S1P by Sphk1 (9, 10).  Thus, 
anthracycline resistance was driven by E2F in an S1P-dependent manner in HNSCC. This was 
consistent with a literature demonstrating that sphingolipids can regulate proliferation, 
differentiation, invasion and apoptotic responses in cancer cells (23-25). Thus, Sphk1 is a key 
enzyme controlling cytotoxic responses in cancer cells (9).  The translational significance of 
this is highlighted by reports that a combination of doxorubicin plus a Sphk1 inhibitor caused 
tumor regression in a xenotransplant model of SCC (9, 10).   
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 Whilst the above findings suggest a link between E2F activity and Sphk1/S1P-dependent 
anthracycline resistance, the relationship and mechanism controlling this pathway remains 
unresolved. For example, E2F1 and E2F7 are both overexpressed in the majority of HNSCC 
and are known to be mutually antagonistic (26).  Therefore, we considered the proposition 
that the increase in E2F-dependent Sphk1 transcription may be due to a pathologica l 
imbalance in the ratio of activating E2F1 to inhibitory E2F7 in the HNSCC.  Consistent with 
this, we report that in greater than 80% of HNSCC there is a selective relocation of E2F7 from 
the nucleus to the cytoplasm. We show this mislocalization is due to exportin 1 (XPO1; also 
known as chromosomal maintenance 1 or CRM1) dependent export of E2F7 from the nucleus 
resulting in derepression of Sphk1.  Finally, we show that pharmacological inhibition of XPO1 
reverses the E2F7 pathology and anthracycline resistance in cell line and patient 
xenotransplant models of  
HNSCC.    
  
Results  
The opposing action of E2F1 and E2F7 control Sphk1 expression and doxorubicin 
resistance. We previously identified the Sphk1/S1P pathway as a unique downstream effector 
of E2Fdependent resistance to anthracyclines such as doxorubicin (9, 10). However, it was 
not determined whether Sphk1 transcription was the result of mutual antagonism between the 
activating E2F1 and the inhibitory E2F7.  To address this, we transfected doxorubicin-
sensitive cell lines, KJDSV40 (EC50 = 0.1 M) and FaDu (EC50 = 0.2 M), and doxorubicin-
resistant cell lines, SCC25 (EC50 = 1.1 M) and Detroit562 (EC50 = 1.2 M), with siRNA 
targeting E2F1 or E2F7.  We achieved a knockdown greater than 70% for the E2F7 protein 
(Fig.1A) and 45% for the E2F1 protein (Fig. 1B) with their cognate siRNAs compared to cells 
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transfected with vehicle or a scrambled control. Treatment with E2F7 siRNA significantly 
enhanced Sphk1 protein expression (Fig. 1C, top panel) whilst treatment with E2F1 siRNA 
significantly reduced Sphk1 protein expression compared to controls (Fig. 1C bottom panel). 
A similar result was observed on the expression of Sphk1 mRNA in the SCC25 cell line 
(Suppl. Fig. 1) as was observed for Sphk1 protein. Finally, as shown by the expression of the 
apoptotic marker cleaved caspase-3, E2F1 depletion significantly increased doxorubic in 
cytotoxicity (Fig. 1D, bottom panel) whilst E2F7 depletion significantly reduced doxorubic in 
cytotoxicity (Fig 1D, top panel).  These data indicate that E2F7 represses Sphk1 expression 
and increases sensitivity to doxorubicin whilst E2F1 induces Sphk1 expression and induces 
doxorubicin resistance in all the tested SCC cell lines. These data show that Sphk1 expression 
and doxorubicin sensitivity are regulated by the opposing actions of E2F1 and E2F7.  
  
 ChIP analysis of extracts from normal human epidermal keratinocytes (HEK's) and the 
doxorubicin-resistant SCC25 cells showed that E2F1 and E2F7 could bind the E2F response 
element within the Sphk1 promoter (Fig. 1E).  These data show that Sphk1 is a direc t 
transcriptional target of the activating E2F1 and the inhibitory E2F7 in HEK's and SCC25 
cells.  Intriguingly, in the SCC25 cells, levels of E2F1 bound to the Sphk1 promoter were 
more than two fold that of E2F7 (Fig. 1E) whilst in HEK's bound levels of E2F7 were higher 
than for E2F1. This contrasts to the observation that E2F7 protein was approximately 2.5 fold 
more abundant than E2F1 in the SCC25 cells (Fig. 1F).  These data indicate that in SCC25 
cells, E2F1 is preferentially bound to the Sphk1 promoter despite the higher levels of total 
cellular E2F7 expression.  Since previous studies showed that other members of the E2F 
family such as E2F4 and 5, are subject to an XPO1-dependent nuclear export (27-29), we 
examined the subcellular localization of E2F1 and E2F7 in SCC25 cells and HEK's to see if 
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this could explain the observed discrepancy between promoter binding and total cellular level 
of E2F7.   
Immunofluorescent analysis of the E2F1 protein, revealed strong nuclear staining in HEK's 
and SCC25 cells. In contrast, we found that E2F7 displayed strong cytoplasmic staining and 
weak nuclear staining in SCC25 cells whilst in HEK’s we detected a strong nuclear staining 
of E2F7 (Fig. 1G). These data indicate that the reduced nuclear localization of E2F7 may 
cause derepression of sphk1 promoter activity and expression in SCC25 cells.   
E2F7 is frequently mislocalised in HNSCC lesions and causes doxorubicin resistance.  To 
extend our observation on the mislocalization of E2F7 in doxorubicin-resistant SCC cells we 
examined the subcellular localization of E2F1 and E2F7 in five different SCC cell lines 
(KJDSV40,  FaDu, Cal27, SCC25  and Detroit562). Immuno-fluorescent (IF) analysis showed 
that E2F1 was predominantly nuclear in all cell types (Fig. 2A). In contrast, we found that 
E2F7 was predominantly nuclear only in the KJDSV40 cells, whereas all the remaining cell 
lines displayed prominent cytoplasmic staining and variable to weak nuclear staining of E2F7 
(Fig  
2A). Moreover, we examined the localization of other XPO1 cargo such as p53, survivin and  
Topoisomerase IIα proteins that have been previously reported to be mislocalised in cancer 
(3035).  However, we found no evidence of their mislocalization in our SCC cell lines and 
HEKs (Suppl. Fig. 2A-C). Thus, the mislocalization defect was selective for E2F7. Given that 
Sphk1 expression is directly controlled by E2F1 and E2F7 we determined whether there was 
a relationship between the relative nuclear E2F1 and E2F7 expression levels and Sphk1 
expression and doxorubicin sensitivity. Firstly, we noted that total cellular protein expression 
levels for  
E2F1, E2F7 and Sphk1 increased proportionately with increasing doxorubicin resistance (Fig. 
2B vs Fig. 1D).  However, when we quantitated the nuclear levels of E2F7 (E2F7nuc) and 
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expressed those as a ratio of total E2F1 present in the nucleus (E2F7nuc/E2F1), we discovered 
a strong association with both Sphk1 expression levels and doxorubicin sensitivity (Fig. 2C). 
These data are consistent with our ChIP and IF data (Fig. 1) and show that the extent of E2F7 
mislocalization in SCC cells correlates with the derepression of Sphk1 expression and 
increasing doxorubicin resistance.   
  
Next we determined whether there was evidence for E2F7 mislocalization in patient 
SCCs.  Immunohistochemical analysis showed that E2F7 was mislocalised in 80% of  
cutaneous or head and neck SCC patient tumors, and confirmed that the localization of E2F7 
was predominantly nuclear in normal epidermal and mucosal keratinocytes (Fig. 2D, E).  The 
major shift in subcellular localization of E2F7 occurs in the transition from normal tissue to 
early cancer, characterized by tumours with no nodal involvement.  However, there was also 
an association between increasing cytoplasmic localization and disease progression in SCCs, 
as characterized by increasing nodal involvement (Fig. 2F). Finally, analysis of additiona l 
cancer tissue microarrays showed that E2F7 was mislocalized in 82% colorectal cancers, 73% 
prostate cancers and 70% breast cancers compared to normal tissue controls (Suppl. Fig. 3).  
Thus, E2F7 mislocalization is a common defect in human cancers which will selective ly 
disrupt the E2F1/E2F7 transcriptional balance.    
  
E2F7 is an XPO1 cargo protein.  Our finding that E2F7 is mislocalised in SCC suggests that 
E2F7 may be subject to nucleocytoplasmic shuttling.  E2Fs 4 and 5 are known to be exported 
from the nucleus via XPO1 (27-29).  Moreover, it is known that XPO1 is overexpressed in a 
number of tumor types including HNSCC (36, 37). However, there are no reports of 
nucleocytoplasmic shuttling of E2F7 (38) and no E2F has been shown to be mislocalised in 
human tumors before.  Thus, we examined whether the mislocalization of E2F7 in SCC was 
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due to XPO1-dependent nuclear export of E2F7. In the first instance, we treated SCC25 cells 
with an XPO1 inhibitor for 4 or 8 hours and examined the subcellular distribution of E2F7 by 
western blotting or immunofluorescence (Fig 3A). This experiment showed that the XPO1 
inhibitor, selinexor (KPT-330), induced nuclear accumulation of E2F7 in SCC25 cells and 
reduced Sphk1 expression (Fig. 3A). Similarly, transfection of an XPO1 siRNA caused a 
similar redistribution of E2F7 to the nucleus in SCC25 cells (Fig. 3B). Moreover, XPO1 
siRNA reduced Sphk1 protein expression to undetectable levels (Fig. 3B). These data were 
confirmed using doxorubicinresistant Detroit cells (Suppl. Figure 4). These are the first data 
to show that E2F7 is an XPO1 nuclear export target. These data also show that the 
mislocalization of E2F7 in drug resistant  
SCC cells is reversible with a pharmacological inhibitor of XPO1. Thus, we examined whether 
combining doxorubicin with an XPO1 inhibitor would also reverse doxorubicin resistance. 
Our data show a strong enhancement of doxorubicin induced cytotoxicity in SCC25 cells 
when combined with selinexor (Fig. 3C & D).  We also observed similar enhancement in 
Detroit and FaDu cells (Fig 3D) which also displayed a mislocalization defect (see Fig 2A).   
These functional data are further supported by our analysis of the E2F7 sequence using the 
LocNES tool for predicting nuclear export signals (38). This analysis showed that E2F7 had 
a strong nuclear export sequence located at aa’s 1-25.    
  
E2F7 mislocalization is a novel actionable pathology in HNSCC. To test the in vivo efficacy 
of a doxorubicin + selinexor combination we generated xenotransplant tumours using SCC 
cells in which E2F7 was mislocalized to the cytoplasm (SCC25 cells or Detroit cells).  
Consistent with our in vitro findings, the SCC25-xenotransplant tumours treated with 
selinexor + doxorubicin showed a profound reduction in tumor growth compared with vehic le 
and single agent treatment groups (Fig. 4A top panels).  Significantly, immunohistochemica l 
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analysis showed that selinexor caused nuclear accumulation of E2F7 in the SCC25 tumours 
(Fig. 4A lower right panel) thus confirming the pharmacological activity of selinexo r. 
Moreover, the doxorubicin + selinexor combination significantly increased the expression of 
the apoptotic marker, cleaved caspase-3 and significantly reduced the expression of the 
proliferation marker Ki67 (Fig 4A middle and lower left panels). Similarly, selinexo r 
relocalized E2F7 to the nucleus of Detroit cells and significantly enhanced sensitivity to 
selinexor + doxorubicin compared to the agents alone as shown by tumour volumes and 
cleaved caspase 3 and Ki67 staining (Suppl. Fig. 5A).    
  
To validate our cell line xenotranplants we repeated the drug treatments in 2 patient 
xenotransplant (PDX) samples of oral SCC which displayed cytoplasmic localization of E2F7 
and 1 PDX in which E2F7 was localised to the nucleus.   Following passage of the origina l 
tumour biopsy in the mouse we generated sufficient 2nd generation PDX tumour-bearing mice 
to examine the effect of the selinexor + doxorubicin combination.  In our hands the PDX 
tumours grew at a variable rate making it difficult to generate meaningful tumour growth rate 
curves across the treatment groups.  Despite this, we found that tumours, in which E2F7 was 
mislocalised, displayed significant increases in cleaved caspase 3 and reduced Ki67 staining 
in all treatment groups compared to the control group (Fig 4B).  However, treatment with 
doxorubicin + selinexor significantly increased cleaved caspase 3 staining and reduced Ki67 
staining compared to those of the agents alone (Fig 4B).  Combined, our data demonstrate that 
selinexor is able to reinstate the nuclear localization of E2F7 resulting in improved sensitivity 
to the cytotoxic effects of doxorubicin in HNSCC.   
  
Finally, we were fortunate to generate a PDX tumour from a primary tumour in which 
E2F7 retained nuclear localization (Suppl Fig 5B).  These tumours implanted and grew in a 
synchronous manner across the 2nd generation mice.  Analysis of the tumour growth curves 
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revealed that this tumour was sensitive to doxorubicin alone and failed to show significant 
enhancement of sensitivity in response to selinexor or the combination (Suppl Fig 5B). These 
data validate our proposition that nuclear expression of E2F7 is required to induce doxorubicin 
sensitivity. Combined, these studies indicate that the E2F7 mislocalization defect could be 
used as a marker to stratify patients for inclusion in future clinica l trials of a selinexor + 
doxorubicin combination.   
Discussion  
  
Approximately 40-50% of patients with advanced HNSCCs will die of their disease due to 
acquired or inherent therapy resistance. Unfortunately, the prognosis for these patients has 
remained unchanged for over four decades due to the lack of therapies to bypass or reverse 
drug resistance (3, 4). Hence, there is a significant clinical unmet need to identify actionable 
targets within drug resistance pathways that can be exploited to overcome therapy resistance. 
We provide evidence that resistance to anthracyclines is driven by E2F in an S1P-dependent 
manner in SCC.  Specifically, we show that anthracycline resistance emerges due to an 
imbalance between the activating E2F1 and the inhibitory E2F7 transcription factors. This 
imbalance is due to the pathological activation of export of E2F7 from the nucleus via the 
XPO1 pathway. Overall, our study is the first to demonstrate i) that E2F7 is subject to XPO1-
dependent nuclear export, ii) that E2F7 is selectively mislocalized in greater than 80% of 
human SCC, iii) that mislocalization of E2F7 in HNSCC causes derepression of Sphk1 and 
its catalytic product, S1P, which, in turn, drives anthracycline resistance and iv) that 
anthracycline resistance is actionable and can be reversed with an inhibitor of XPO1 in 
xenotransplant models of HNSCC.   
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E2F1 and E2F7 are mutually antagonistic yet both are often overexpressed in cancers 
such as SCC (9).  Despite their mutually antagonistic activity, cancers are often characterized 
by upregulation of E2F-dependent gene targets suggesting an imbalance between the 
activating and inhibitory E2Fs (26).  Our study provides a credible explanation as to how 
simultaneous elevation of the mutually antagonistic E2F1 and E2F7 results in a transcriptiona l 
bias favoring overexpression of E2F-dependent genes and E2F-dependent pathways in SCC. 
Specifically, we have shown that the export of E2F7 from the nucleus leads to derepression 
of E2F target genes such as Sphk1 (9).  Moreover, it provides a likely explanation for the 
overexpression of other E2F target genes such as RACGAP1, E2F1 & 7 in SCC (9, 10).   E2F7 
is a direct transcriptional target of E2F1 and E2F1 is a direct transcriptional target of itself and 
E2F7. In this way E2F1 and E2F7 expression levels self-regulate.  This balance is disrupted 
when E2F7 is selectively exported from the nucleus leading to derepression of E2F1 which in 
turn induces E2F1 and E2F7 expression. This pathology alone could explain many of the E2F-
dependent effects observed in SCC such as hyperproliferation, drug resistance and aberrant 
differentiation. Significantly, we found evidence that this pathology exists in other cancer 
types such as lung, colorectal and breast cancer as well (Suppl 3).  Thus, strategies that relocate 
E2F7 to the nucleus could potentially restore an E2F1/7 balance and normalize E2F-dependent 
functions in SCC-derived keratinocytes and possibly other tumour types.  
  
  The present study highlights a novel E2F-dependent S1P axis  
responsible for anthracycline resistance in SCC. The activation of this drug resistance axis is 
a direct result of the mislocalization of E2F7 and the consequent derepression of Sphk1 
expression.  Earlier work has shown that Sphk1 is a direct transcriptional target of E2F7 and 
E2F1 (9). However, the relative contribution of E2F1 and E2F7 to Sphk1 transcription was 
not determined. We now show that E2F1 (activator) and E2F7 (inhibitor) compete for binding 
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to the Sphk1 promoter. Thus, the mislocalization of E2F7 results in an E2F1-dependent 
induction of Sphk1 expression. This is supported by ChIP analysis of E2F1 and E2F7 binding 
to the Sphk1 promoter in normal human keratinocytes and SCC cells. Moreover, knockdown 
of E2F1 reduced  
Sphk1 expression and enhanced doxorubicin sensitivity whilst knockdown of E2F7 
derepressed Sphk1 expression and reduced doxorubicin sensitivity. Finally, whilst E2F1 and 
E2F7 were both overexpressed in SCC cell lines, the level of Sphk1 promoter binding, Sphk1 
expression and doxorubicin sensitivity correlated with the relative amount of E2F1 to E2F7 
within the nucleus but not the total cellular expression levels. These data show the critica l 
dependence of Sphk1 expression and doxorubicin sensitivity on the opposing action of E2F1 
and E2F7. Since dysregulation of the Rb:E2F axis is a common defect in SCC (9, 26) resulting 
in E2F activation then this is likely to explain the overexpression of Sphk1 and doxorubic in 
resistance observed in HNSCC. This would also suggest that the mislocalization is a 
consequence of neoplastic transformation rather than a driver of transformation. Finally, the 
observation that E2F7 knockdown can induce Sphk1 expression and doxorubicin resistance 
would suggest that these are non-redundant functions of E2F7. This extends our understand ing 
of the complexity of the  
E2F family since earlier studies with murine skin painting SCC models identified E2F7 and 
E2F8 shared non-redundant properties (9).     
  
 We have established a direct link between the mislocalization of E2F7 and Sphk1/S1P 
induced anthracycline resistance.  The mechanism by which Sphk1/S1P induces anthracycline 
resistance cannot be attributed to a global anti-apoptotic mechanism such as activation of 
BH2/3 domain proteins (eg BCL2) or PI3K/AKT activation. Supporting this is the observation 
that a combination of Sphk1 inhibition (genetic or pharmacologic) is able to reverse 
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anthracycline resistance but is unable to alter responses to other cytotoxic agents such as 
cisplatin (9, 10).  Similarly the use of an XPO1-selective inhibitor can restore E2F7 nuclear 
localization and reverse resistance to doxorubicin and etoposide but not to taxol (suppl 6).  
Thus, the mechanism by which E2F7 mislocalization induces anthracycline resistance is 
context-specific.  Previous studies have shown that E2F activity is linked to the sensing and 
repair of DNA damage in the context of murine cutaneous SCC (26).  Doxorubicin is known 
to induce double strand DNA breaks and so the E2F/Sphk1/S1P axis may work via modulat ion 
of responses to doxorubicininduced DNA damage. Regardless of mechanism, the link 
between the mislocalization of E2F7 and Sphk1/S1P induced anthracycline resistance 
provides a unique translational opportunity since the E2F/Sphk1/S1P axis is actionable via 
pharmacological inhibitors of Sphk1 (9) or XPO1 in combination with doxorubicin. Lending 
support to the potential clinical value of targeting E2F/Sphk1/S1P pathway is the observation 
that the majority of cutaneous and HNSCC express high levels of E2F1, E2F7, Sphk1 and 
another E2F target, RACGAP1 (9, 10).  The high levels of expression of these E2F-dependent 
targets accompany a poor outcome and suggest that the reinstatement of a “normal” nuclear 
E2F balance may reverse many of these poor prognostic  
features of SCC.    
  
 As far as we are aware, this is the first report showing that any E2F isoform is mislocal ised 
in any cancer type. Indeed, we show that E2F7 mislocalization is a common pathology in 
multiple cancer types such as HNSCC, cutaneous SCC, prostate, colorectal or breast cancer.  
Central to this, our data shows that E2F7 is a bona fide cargo for XPO1dependent nuclear 
export.  This is supported by data showing that i) E2F7 contains a high confidence NES 
between aa 1-25 (38) and ii) E2F7 can be relocalised to the nucleus following treatment with 
XPO1 siRNA or selinexor. The identification of this novel pathology has clinical and 
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therapeutic implications for the management of HNSCC. Defects in XPO1 activity have been 
reported in many cancers.  Indeed, mutation of the NES in cargo proteins has been shown to 
cause defects in XPO-1 dependent nuclear export of BRCA2 in breast cancer (39).  This is not 
the case for the mislocalization of E2F7 as there is no evidence in public databases for 
mutations in E2F7 NES in HNSCC or other cancer types (38).  Similarly, whilst SCCs 
overexpress XPO1 it is unlikely that this is the reason for the defect in HNSCC.  For instance, 
toposomerase II , p53, survivin and E2F1 are established cargo of XPO1 yet we found no 
evidence for their exclusion from the nucleus in our SCC cells (Suppl Fig 2).  In contrast, 
E2F7 displayed a mislocalization phenotype in greater than 80% of human SCC.  These data 
suggest that keratinocytes and SCC cells possess a selective mechanism for “marking” E2F7 
for export which is context-specific and dissimilar to other XPO1 cargo proteins. This is not 
unprecedented since context-specific nuclear export clearly occurs in normal keratinocytes. 
For example, E2F5 nuclear export is selectively reduced during squamous differe ntiation and 
E2Fs 4 and 5 display differential subcellular localization in keratinocytes despite both being 
XPO1 cargo (27-29).  Thus, E2F7 mislocalization is a common context-specific pathology in 
SCC and results in Sphk1 induction and anthracycline resistance.      
  
 Inhibition of XPO1 activity has been exploited to kill various cancer cell types in vitro and in 
vivo (37, 40-43).  Indeed, there is considerable enthusiasm for this class of agents with 
multiple clinical trials of selinexor, underway.  Data from earlier trials show selinexor to be 
tolerated at doses sufficient to show evidence of XPO1 inhibition (35 mg/m2; 53).  Moreover, 
early results indicate that blood cancers may be more sensitive to selinexor than solid tumours 
(44, 45).  Indeed, the most recent trial of selinexor in relapsed ALL resulted in 47% of patients 
achieving a complete response (46).  Our study suggests that reversal of the E2F7 nuclear 
export defect using selinexor in combination with anthracyclines may provide a unique 
105 
 
therapeutic opportunity to treat SCC. The reversal of drug resistance appears to be restricted 
to anthracyclines or etoposide since we saw no evidence for improved sensitivity when 
selinexor is combined with taxol (suppl 6).  It is noteworthy that recent reports in myeloma 
cells has shown that selinexor is able to reinstate nuclear localization of Topo IIA in multip le 
myeloma cells and make them sensitive to topoisomerase inhibition (42). Whilst we observed 
no defect in topoisomerase II  localization in the SCC cells it is clear that E2F1-dependent 
activation of the Sphk1/S1P axis acts to suppress the cytotoxic action of anthracyclines and 
topo II  inhibitors in SCC cells.  Our data support the initiation of a human clinical trial to 
test the efficacy of an anthracycline plus selinexor in relapsed SCC patients with evidence of 
E2F7 mislocalization.      
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Materials & Methods  
Cell culture:  Human epidermal keratinocytes (HEKs) were isolated and cultured from 
neonatal foreskins as described previously (9). HEKs were grown in low-calcium serum-free 
keratinocyte media (Invitrogen, Sydney, NSW, Australia).  Isolated HEKs were mainta ined 
as proliferative cultures and were serially cultured for up to 4 passages. The SCC25 and 
Detroit562 cell lines were purchased from ATCC (Cryosite, South Granville, Australia). 
KJDSV40*, Cal27** and FaDu** cell lines were generous gifts from the laboratories of Dr 
Phillip Gallimore in Birmingham, UK (*) and Dr Elizabeth Musgrove in the Garvan Institute, 
Sydney, Australia (**) and were authenticated by short tandem repeat genotyping. The SCC 
cell lines were maintained in 1:1 DMEM: Ham’s F12 nutrient mix pH 7.1 media (Life 
technologies, Australia) as previously described (9).   
  
Immunohistochemistry and tissue microarrays:  Immunohistochemistry was 
performed on formaldehyde-fixed, paraffin-embedded slides as described previously (19). 
Briefly, deparaffinised slides were rehydrated and incubated with a Tris-EDTA pH 9.0 (10mM 
Tris Base, 1mM EDTA, 0.05% Tween 20) antigen retrieval solution in a decloaking chamber 
(Biocare  
Medical). Non-specific antibody binding was blocked with 10% foetal bovine serum 
(Bovogen Biologicals, Essendon, Australia) for one hour followed by overnight incubation 
with anti-E2F7 (1:50; Abcam, ab56022), anti-E2F-1 (1:100; Santa Cruz KH95), ki67 (1:1000, 
Abcam, ab15580) or anti-cytokeratin 5/6  (1:100; Novus Biologicals) primary antibodies. To 
visualise antigens, slides were washed and incubated for one hour with anti-rabbit (GE 
healthcare, NA934V) or anti-mouse (Life technologies, 626520) IgG secondary antibody 
conjugated with Horseradish peroxidase (GE healthcare, NA934V) and Cardassian DAB 
chromogen (Biocare Medical).  
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Normal rabbit (Dako, X0936) or normal mouse (Santa Cruz, SCZSC-2025) IgG was used as 
negative control. Expression of cleaved caspase-3 protein was detected using the SignalSta in 
Apoptosis IHC detection kit (Cell Signaling technology, 12692s).The tissue microarrays with 
reference numbers SK802a, HN483, HNT1021 and TMA2401a, were purchased from US  
Biomax, Inc. An additional tissue microarray was constructed by Dr. Marcin Dzienis and Dr.  
Ana Cristina Vargas at the Medical Oncology Department of the Princess Alexandra Hospital, 
Australia as described (9). Staining localization and intensity was evaluated by a pathologis t 
using a modified quick score method described previously (47). The pancreatic, breast and 
colorectal tissue and carcinomas cores from the tissue microarrays with reference number  
TMA2401a was processed using the VENTANA platform according to the manufacture r’s 
instructions. All images were processed using the “auto contrast” tool from Adobe Photoshop 
CC 2017.   
  
 siRNA delivery and Transfections:  Approximately 3x103 SCC cells were plated into 6well 
plates and transfected with validated siRNA sequences targeting β-Galactosidase 
(SigmaAldrich, WD01043455), E2F7 (9), E2F1 (Sigma-Aldrich), or XPO1/CRM1 
(ThermoFisher, s14937) using Lipofectamine 2000 Transfection Reagent (Invitrogen) 
according to the manufacturer’s instructions.  
Immunofluorescence:  Approximately 3x104 Normal HEKs or SCC cells were plated 
onto 12 mm cover slips (ProSci Tech). The next day, cells were treated with either i) 1:1000 
dimethyl sulfoxide (DMSO) (Sigma-Aldrich),  ii) 5 µl/ml of Lipofectamine 2000,  iii) 1 µM 
selinexor (Karyopharm therapeutics,  iv) 25 nM of β-Galactosidase control siRNA or v) 25 
nM  
XPO1-targeting siRNA (ThermoFisher, s14937). Cover slips were then, fixed with  4% 
Paraformaldehyde (Histopot, Australian Biostain) for 15 minutes and permeabilized with 
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0.1% Triton X-100 (Lab Chem) for an additional 20 minutes. The cells were blocked in 2% 
BSA (Sigma-Aldrich) solution for 30 minutes followed by incubation with anti-E2F7 (1:50), 
anti- 
E2F1 (1:100), anti-topoisomerase IIα (1:100; Abcam AB52934), anti-survivin (1:100; Cell 
signalling, 71G4B7), or anti-P53 (1:100; Santa Cruz, SC-6243) primary antibodies. A 
secondary anti-Rabbit (1:100; LifeTechnologies, A11070) or anti-mouse (1:100; Invitrogen, 
A-11001) antibodies conjugated with Alexa Fluor® 488 were used for protein detection. 
Nuclei and actin filaments were counterstained with DAPI (Cell signalling, 4083s) and 
Phalloidin (Santa Cruz, SCZSC-363795) respectively. The solutions described for fixation, 
permeabilization and blocking were used at 4 0C. Normal rabbit or mouse IgG were used as 
negative control.  
Immunostaining was visualized using a Zeiss LSM 510 Meta confocal microscope.  
  
Protein isolation and Immunoblotting:  Cell lysis and separation of the nuclear and 
cytoplasmic fractions were done using the NE-PER Nuclear and Cytoplasmic Extraction Kit  
(ThermoFisher Scientific, 78833) according to manufacturer’s instructions. Total protein was 
extracted using RIPA buffer (150 mM NaCl, 20 mM Tris, 1% Triton X-100, 0.1% SDS, 0.5% 
sodium deoxycholate, pH 8.0). Total or fractionated subcellular proteins (20 µg) were then 
resolved in a 10% SDS-PAGE gel and transferred onto a polyvinylidene fluoride membrane 
(Immobilon FL, Millipore, Kilsyth, Australia). Membranes were exposed to one of the 
following primary antibodies for at least 12 hours: anti-E2F7 (1:500), anti-E2F1 (1:1000), 
anti-AKT (1:2000; Gene search, 9272S), anti-XPO1 (1:1000; Sigma-Aldrich, 37784),  anti-
ASH2L (1:2000; Cell signalling, D93F6), anti-Caspase-3 (1:1000; Cell Signalling, 9662), 
anti-Cleaved caspase-3 (1:1000; Cell Signalling, 96615), anti-Actin (1:4000; SantaCruz, sc-
44778) anti-Sphk1 ( 1:1000; Sigma-Aldrich HPA022829). To visualise the results, the 
109 
 
membranes were incubated for 1 hour with an anti-Rabbit or anti-Mouse IgG Secondary 
Antibodies conjugated with Horseradish peroxidase. The reaction was developed using the 
Super Signal West Pico ECL reagent (Pierce, ThermoFisher Scientific) and a FusionSL 
detection system (Vilber Lourmat).  
Quantitative analysis of protein concentration was performed using Image J (Wayne Rasband, 
National Institutes of Health, USA).   
Quantitative RT-PCR: Total RNA was isolated with TRIsure reagent (Bioline, 
BIO38032) and cDNA was prepared using the Tetro cDNA Synthesis Kit (Bioline, BIO-
65042), according to manufacturer’s instructions. qRT-PCR was performed as described 
previously (21), using the following primer sequences:  
Sphk1Forward:AAGACCTCCTGACCAACTGC;  
Sphk1Reverse:GGCTGAGCACAGAGAAGAGG;  
E2F1Forward:TCCAAGAATCATATCCAGTGGCT;  
E2F1Reverse: GCTGGAATGGTGTCAGCACAGCG;  
E2F7Forward:GTCAGCCCTCACTAAACCTAAG;  
E2F7Reverse:TGCGTTGGATGCTCTTGG;  
TBPForward: TCAAACCCAGAATTGTTCTCCTTAT;  
TBPReverse: CCTGAATCCCTTTAGAATAGGGTAGA   
  
 Chromatin immunoprecipitation (ChIP): DNA from  4x106 cells was collected, precleared  
using 20 μL of Protein G magnetic beads (Cell Signaling Technology) and fragmented using 
micrococcal nuclease as per  the Simple ChIP Enzymatic Chromatin IP kit  
(Magnetic) (Cell Signaling Technology) manufacturer’s instructions. Precleared and 
fragmented DNA samples were incubated overnight at 4 0C with normal rabbit IgG (Cell 
Signaling Technology), anti- E2F1 (1:1000; Santa Cruz, sc-193) or anti-E2F7 (1:100; Abcam, 
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ab56022) antibodies. Quantitative PCR of the Sphk1 promoter binding region and relative 
enrichment was calculated as described in (9).  The following Sphk1 promoter primers were 
used,forward: GGGACCCTTGGTTTCACCTC and 
reverse; GAATTTCGGGTGGGCTAGGG.    
  
 Viability assays:  Cell viability after treatment with siRNAs or drugs was analysed using the 
Cell Titer 96 Aqueous One Solution Cell (Promega, Alexandria, Australia) according to 
manufacturer’s instructions. Briefly, 7.5x103 SCC cells were plated in triplicate in 96-well 
plates and allowed to adhere for 24 hours before treatment with vehicle (DMSO), 100 nM 
E2F7targeting siRNA or 1 µM selinexor alone or in combination with increasing 
concentrations of doxorubicin (0-3 µM) for 48 hours. Viability was quantified by reading the 
absorbance at 490 nm in a MultiSkan FC Microplate Photometer (Thermo Fisher Scientific ). 
The data was analyzed using GraphPad Prism V5 software.  
  
 Generation of a patient derived xenograft (PDX) animal model:  Human SCC tissue samples 
were obtained from patients with primary and secondary squamous cell carcinoma after 
surgical biopsy. All samples were obtained with patient consent and approval from our 
Institutional Ethics Committee.  The tumors were then decontaminated (overnight incubation 
with 10 ng/ml penicillin, streptomycin, and gentamicin and 200ng/ml amphotericin B), coated 
with matrigel (Falcon) and implanted into a subcutaneous “pocket” created in the scruff of the 
neck of a non-obese diabetic/severe combined immunodeficient (NOD/SCID) female mouse.  
“First generation” tumors were allowed to grow until they reached 10 mm in diameter and 
were then passage into 16 NOD/SCID “second generation” females. The “second generation” 
tumors were allowed to grow and were used for drug efficacy testing. The animal studies all 
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had approval from our Institutional Bioethics Committee.  The establishment of the HNSCC 
PDX model is being prepared for publication elsewhere.  
  
 In vivo drug efficacy testing:  In vivo drug efficacy was determined using our PDX model or 
cell line xenotranplant models. For xenotransplant model, female NOD/SCID mice were 
injected subcutaneously with 1.5x106 SCC25 or Detroit562 or FaDu cells and tumours 
allowed to grow. Once the xenotransplant or PDX tumour reached 4 mm in diameter, they 
were randomly assigned to 4 groups and mice treated twice per week for three weeks with i) 
vehicle  
(0.6% plasdone PVP K-29/32 and 0.6% Poloxamer pluronic F-68), ii) 0.5 mg/kg doxorubicin  
(Sigma-Aldrich), iii) 15 mg/kg selinexor or iv) 15 mg/kg selinexor + 0.5 mg/kg doxorubicin. 
Mice were monitored twice per week for changes in weight and tumour size. Animals were 
sacrificed at the end of the three-week period or if the tumour size reached 10 mm in diameter. 
Student’s t test with 95% confidence was used to calculate statistical significance (GraphPad 
Prism V5 software).  
  
Study approvals: The work presented in this manuscript is covered by Approvals from the  
Princess Alexandra Hospital Human Ethics Committee (HREC/14/QPAH/150) and the  
University of Queensland Animal Ethics Committee (UQDI/357/17).   
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Fig. S1. E2F1 and E2F7 controls Sphk1 mRNA expression.  
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Fig. S3. Subcellular mislocalization of E2F7 is a common defect in prostate, colon and breast 
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Fig. S5.  E2F7 mislocalization is a novel actionable pathology in HNSCC  
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Figure 1. The opposing transcriptional actions of the activator E2F1 and the inhibitory 
E2F7 control Sphk1 expression and doxorubicin resistance in normal tissue and SCC cell 
lines. A, B. The efficacy of E2F7 or E2F1-targeting siRNAs to knock down the expression of 
their cognate targets in KJDSV40 (abbreviated KJD), FaDu, SCC25 and Detroit562 
(abbreviated Detroit) cells was analyzed by quantitative western blot analysis of E2F1 (A) and 
E2F7 (B) proteins. Anti-ß actin antibody was used as loading control. Quantitative data 
represents mean ± SD of triplicate determinations of 2 biological replicates. C. Representative 
western blot (left panel) and quantitative analysis of KJD, FaDu, CAL27, SCC25 and Detroit 
cells treated with i)vehicle, ii)control β-Galactosidase siRNA  iii) E2F7-targeting siRNA iv) 
E2F1-targeting siRNA for 48 hours showing the expression of Sphk1. Normalization and 
quantitation as described in A. D.  Representative western blot (left panel) and quantitat ive 
analysis of cleaved caspase 3 in KJD, FaDu, CAL27, SCC25 and Detroit  cells treated with i) 
vehicle, ii) control β-Galactosidase siRNA + 1 µM doxorubicin  iii) E2F7-targeting siRNA+1 
µM doxorubicin  iv)  E2F1-targeting siRNA + 1 µM doxorubicin for 48 hours. Total caspase-
3 was used as control for cleaved caspase-3 changes in expression. Normalization and 
quantitation as described in A. E. ChiP analysis of EF1 and E2F7 binding to the Sphk1 
promoter in HEK's and SCC25 cells. Nonimmune IgG was used as control. Quantitative data 
represents mean ± range; of 2 biological replicates. F. Representative western blot (left panel) 
and quantitative analysis (right panel) of total extracts of proliferating HEK's and SCC25cells. 
β-actin was used as loading control and expression levels plotted as E2F7/E2F1 ratio. G. 
Immunoflourescence analysis showing the intracellular localization of E2F7 and E2F1 in 
proliferating HEK's and SCC25 cells. Images are representative of at least three replicates.    
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Figure 2. Subcellular mislocalization of E2F7 is a common defect in HNSCC lesions and 
accompanies doxorubicin resistance. A. Subcellular localization of E2F7 and E2F1 was 
detected by immunofluorescence in KJD, FaDu, Cal27, SCC25 and Detroit cell lines. 
DAPIcounterstained nuclei in blue, phalloidin-counterstained actin filaments in red, and the  
merge column displays E2F7 or E2F1 in green. Images are representative of three biologica l 
replicates. B. Representative western blot (left panel) and quantitative analysis (right panel) 
of total protein extracts from KJD, FaDu, Cal27, SCC25 and Detroit cell lines. Membranes 
were probed for E2F1, E2F7 and Sphk1. Actin was used as loading control. Quantitative data 
represents mean ± SD of triplicate determinations of 3 biologica l replicates. C. Nuclear and 
cytoplasmic fractions from KJD, FaDu, CAL27, SCC25 and Detroit cells were analyzed for 
E2F7 and E2F1by western blot. ASH2L and AKT expression were used as a reference of 
purity of the nuclear and cytoplasmic fractions respectively. Actin was used as loading control. 
The EC50 values for KJD, FaDu, CAL27, SCC25 and Detroit cells treated for 48 hours with 
increasing concentration of doxorubicin (0-3 µM) were calculated using data from triplica te 
determinations of 3 biological replicates. Quantitative data for E2F7nuc/E2F1nuc (right lower 
panel) represents mean ± SEM of triplicate determinations of 2 biological replicates. D. 
Normal epithelia and head and neck squamous cell carcinomas from tissue microarrays were 
stained for E2F1 and E2F7. Representative expression patterns of E2F7 were classified as 
nuclear if the staining was detected only in the nucleus or nuclear/cytoplasmic (N/C) if the 
staining was found in both the cytoplasm and nucleus or cytoplasmic if the staining was 
predominantly localized to the cytoplasm; Individual examples are shown. All analysis was 
carried out by a qualified histopathologist in a blinded analysis. E. For quantitative analysis, 
we pooled data from cytoplasmic or nuclear/cytoplasmic and referred to it as N/C.  The 
number of normal epithelium and squamous cell carcinomas tissue microarrays cores with a 
nuclear or N/C E2F7 expression pattern was quantified; Results are shown as percentage. F. 
The number of metastatic regional lymph nodes was correlated in squamous cell carcinomas 
microarrays and compared with normal epithelium microarrays cores; Results are shown as 
percentage.  
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Figure 3. E2F7 is an XPO1 cargo protein. A, B. Representative western blot (left panel) and 
quantitative analysis (middle panel) of nuclear and cytoplasmic expression of E2F7 and total 
expression of Sphk1 in SCC25 cells (A) treated with 1 µl/ml DMSO for 8 hours or 1 µM 
selinexor for 4 or 8 hours or (B) treated with 5 µl/ml of LP for 32 hours 25 nM of 
βGalactosidase control siRNA for 32 hours or 25 nM XPO1-targeting siRNA for 24 or 32 
hours.  The membranes were probed for E2F7, Sphk1, XPO1, ASH2L, AKT and ACTIN. 
ASH2L and AKT were used for normalization of subcellular fractions and ACTIN as loading 
control. Data presented as mean ± SD of triplicate determinations of biological replicates. 
Changes in subcellular location of E2F7 after treatment with 1 µM selinexor (A, bottom panel) 
or 25 nM XPO1-targeting siRNA (B, bottom panel) were confirmed by immunofluorescence. 
C In top panel, western blot analysis of vehicle and 1 µM selinexor-treated SCC25 cells 
showing expression of full length and cleaved caspase-3. Actin antibody was used for 
normalization. Bottom panel showing a cytotoxicity assay of vehicle and 1 µM selinexor -
treated SCC25 cells exposed to increasing concentrations of doxorubicin (0-3 µM) for 48 
hours. Data presented as mean ± SEM of triplicate determinations from 3 biological replicates. 
D Cytotoxicity assay of vehicle and 1 µM selinexor-treated Detroit, Cal27 or FaDu cells 
exposed to increasing concentrations of doxorubicin (0-3 µM) for 48 hours. Data presented as 
mean ± SEM of triplicate determinations from 3 biological replicates.  
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Fig. 4. E2F7 mislocalization is a novel actionable pathology in HNSCC  A. Xenotransplant 
model for SCC25 (A) and  patient derived xenotransplants from 2 tumor donors (B) were 
generated and mice were treated for 14 days with i) vehicle (0.6% plasdone PVP K-29/32 and 
0.6% Poloxamer pluronic F-68), ii) 0.5 mg/kg doxorubicin, iii) 15 mg/kg selinexor, iv) 15 
mg/kg selinexor + 0.5 mg/kg doxorubicin. Mice were sacrificed 5 days following cessation of 
treatment or at attainment of an ethically- imposed threshold. A. Values of the tumor growth 
curve are presented as mean +/- SEM (n = 4). Resected tumors at completion of the study are 
shown in top right panel. Middle row shows the expression of apoptosis (Cleaved caspase-3) 
and proliferation (Ki-67) markers in resected tumors and its quantitative analysis is shown in 
left bottom panel.  
Quantitative analysis represents percentage of positive cells presented as mean ± SEM of 2-4 
tumors.  In bottom right panel, images showing H&E staining or E2F7 or the human-specific 
marker CK5/6. B. Representative images and quantitative analysis of PDX resected tumors 
showing the expression of apoptosis and proliferation markers. . Quantitative analysis 
represents percentage of positive cells presented as mean ± SEM of quadruplica te 
determinations from at least 2  tumors.   
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Supplementary Figure 1. E2F1 and E2F7 controls Sphk1 mRNA expression. A-B.  
Quantitative RT-PCR assay of SCC25 cells treated for 48 hours with 100 nM vehicle siRNA, 
or 100 nM E2F7 targeted siRNA (A) or 100 nM E2F1 targeted siRNA (B). Data presented as 
mean ± SEM of triplicate determinations from 2 biological replicates.   
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Supplementary Figure 2.Expression pattern of validated XPO-1 cargo proteins in SCC cell 
lines. Subcellular localization of survivin (A), Topoisomerase IIα (B) and P53 (C), was 
detected by immunofluorescence in the SCC25 cell line. The merge column displays DAPI- 
counterstained nuclei in blue, phalloidin-counterstained actin filaments in red, and in green 
survivin or Topoisomerase IIα or P53. Images are representative of at least three biologica l 
replicates.  
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Supplementary Figure 3. Subcellular mislocalization of E2F7 is a common defect in 
prostate, colon and breast carcinomas. A-C. Normal epithelia and carcinomas tissue 
microarrays cores from colon (A), prostate (B) and breast (C) tissue were stained for E2F1 
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and E2F7. The expression pattern of E2F7 was classified as nuclear if the staining was 
detected only in the nucleus, N/C if the staining was found in both the cytoplasm and nucleus 
or the cytoplasm alone; Individual examples are shown. All analysis was carried out in a 
blinded analysis. The number of normal epithelium and carcinomas tissue microarrays cores 
with a nuclear or N/C E2F7 expression pattern was quantified; Results are shown as 
percentage.    
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Supplementary Figure 4. E2F7 is an XPO1 cargo protein. A, B. Immunofluoresence analysis 
of Detroit cells to determine changes in the subcellular localization of E2F7  after treatment 
with 1 µM selinexor (A) or 25 nM XPO1-targeting siRNA (B).  (C) Representative western 
blot (left panel) and quantitative analysis (right panel) of nuclear and cytoplasmic expression 
of E2F7 in Detroit cells treated with vehicle, 25 nM of β-Galactosidase control siRNA for 32 
hours or 25 nM XPO1-targeting siRNA for 8, 24 or 32 hours.  The membranes were probed 
for E2F7, XPO1, Sphk1, ASH2L, AKT. ASH2L and AKT were used for normalization of 
subcellular fractions and loading control. Data presented as mean ± SD of triplica te 
determinations of biological replicates.   
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Supplementary Figure 5.  E2F7 mislocalization is a novel actionable pathology in HNSCC 
A. Xenotransplant model for Detroit (A) and a patient derived xenotransplant model (B) were 
generated and mice were treated for 14 days with i) vehicle (0.6% plasdone PVP K-29/32 and 
0.6% Poloxamer pluronic F-68), ii) 0.5 mg/kg doxorubicin, iii) 15 mg/kg selinexor, iv) 15 
mg/kg selinexor + 0.5 mg/kg doxorubicin. Mice were sacrificed 5 days following cessation of 
treatment or at attainment of an ethically- imposed threshold. A. Values of the tumor growth 
curve are presented as mean +/- SEM (n = 4). In top right panel, images showing H&E staining 
or E2F7 or the human-specific marker CK5/6. Bottom row shows the expression of apoptosis 
(Cleaved caspase-3) and proliferation (Ki-67) markers in resected tumors and its quantitat ive 
analysis.  
Quantitative analysis represents percentage of positive cells presented as mean ± SEM of 2-4 
tumors.  B. Values of the tumor growth curve of PDX tumors are presented as mean +/- SEM 
of triplicate determinations.  The right panel shows H&E staining or E2F7 of the parental 
tumor.  
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Supplementary Figure 6.  Cytotoxic effect of the selinexor/taxol combination on SCC25 
cells. Cytotoxicity assay of vehicle and 1 µM selinexor-treated SCC25 cells exposed to 
increasing concentrations of taxol (0-60 µM) for 48 hours. Data presented as mean ± SEM of 
triplicate determinations from 2 biological replicates.   
 
 
